<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12785482</article-id><article-id pub-id-type="pmcid-ver">PMC12785482.1</article-id><article-id pub-id-type="pmcaid">12785482</article-id><article-id pub-id-type="pmcaiid">12785482</article-id><article-id pub-id-type="doi">10.3390/ijms27010362</article-id><article-id pub-id-type="publisher-id">ijms-27-00362</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Postbiotics Combination Synergises the Antiproliferative Effects of Doxorubicin in Gastric Cancer Cells: A Cellular and Molecular Deep Dive</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9788-8373</contrib-id><name name-style="western"><surname>Eladwy</surname><given-names initials="RA">Radwa A.</given-names></name><xref rid="af1-ijms-27-00362" ref-type="aff">1</xref><xref rid="af2-ijms-27-00362" ref-type="aff">2</xref><xref rid="c1-ijms-27-00362" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fares</surname><given-names initials="M">Mohamed</given-names></name><xref rid="af3-ijms-27-00362" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9337-2441</contrib-id><name name-style="western"><surname>Alsherbiny</surname><given-names initials="MA">Muhammad A.</given-names></name><xref rid="af4-ijms-27-00362" ref-type="aff">4</xref><xref rid="af5-ijms-27-00362" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names initials="D">Dennis</given-names></name><xref rid="af1-ijms-27-00362" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7789-2209</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="CG">Chun-Guang</given-names></name><xref rid="af1-ijms-27-00362" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9736-0197</contrib-id><name name-style="western"><surname>Bhuyan</surname><given-names initials="DJ">Deep Jyoti</given-names></name><xref rid="af1-ijms-27-00362" ref-type="aff">1</xref><xref rid="af6-ijms-27-00362" ref-type="aff">6</xref><xref rid="c1-ijms-27-00362" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Yuan</surname><given-names initials="S">Shu</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Tanaka</surname><given-names initials="T">Takuji</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-27-00362"><label>1</label>NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia; <email>d.chang@westernsydney.edu.au</email> (D.C.); <email>c.li@westernsydney.edu.au</email> (C.-G.L.)</aff><aff id="af2-ijms-27-00362"><label>2</label>Department of Pharmacology, Faculty of Pharmacy, Egyptian Russian University, Badr City 11829, Egypt</aff><aff id="af3-ijms-27-00362"><label>3</label>Sydney Pharmacy School, The University of Sydney, Sydney, NSW 2006, Australia; <email>mohamed.metwaly@sydney.edu.au</email></aff><aff id="af4-ijms-27-00362"><label>4</label>Pharmacognosy Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt; <email>m.ali@victorchang.edu.au</email></aff><aff id="af5-ijms-27-00362"><label>5</label>Freedman Foundation Metabolomics Facility, Victor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia</aff><aff id="af6-ijms-27-00362"><label>6</label>School of Science, Western Sydney University, Penrith, NSW 2751, Australia</aff><author-notes><corresp id="c1-ijms-27-00362"><label>*</label>Correspondence: <email>22027531@student.westernsydney.edu.au</email> (R.A.E.); <email>d.bhuyan@westernsydney.edu.au</email> (D.J.B.)</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2026</year></pub-date><volume>27</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">503380</issue-id><elocation-id>362</elocation-id><history><date date-type="received"><day>05</day><month>12</month><year>2025</year></date><date date-type="rev-recd"><day>20</day><month>12</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>10</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-10 00:25:12.930"><day>10</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution (CC BY) license</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-27-00362.pdf"/><abstract><p>Short-chain fatty acids (SCFAs) acetate, propionate, and butyrate are microbial metabolites with recognised roles in gut and immune homeostasis, but their therapeutic relevance in gastric cancer, particularly in combination with chemotherapeutics, remains unclear. This study investigated the antiproliferative synergy between a combined SCFA mixture (APB) and doxorubicin (Dox) in AGS gastric adenocarcinoma cells using integrated cellular, molecular, and proteomic approaches. APB and Dox each inhibited cell proliferation, with IC<sub>50</sub> values of 568.33 &#177; 82.56 &#956;g/mL and 0.22 &#177; 0.04 &#956;g/mL, respectively, and their combination (3000 + 0.27 &#956;g/mL) enhanced cytotoxicity, achieving 103.46% inhibition and reducing the APB IC<sub>50</sub> to 512.80 &#177; 18.37 &#956;g/mL. Combination index values confirmed synergistic interactions (CI<sub>50</sub> = 0.61; CI<sub>95</sub> = 0.13). APB+Dox significantly increased apoptosis (94.83%) with minimal necrosis (4.64%) and induced strong ROS generation comparable to APB alone, while Dox showed limited oxidative effects. Proteomic profiling revealed downregulation of ribosomal proteins and cell cycle regulators in Dox and APB+Dox groups, with the combination further enhancing apoptosis-related pathways and stress responses. Overall, these findings indicate that SCFA-based interventions, exemplified by APB+Dox, may offer a low-toxicity strategy to potentiate chemotherapy efficacy in gastric cancer through apoptosis induction, redox disruption, and attenuation of drug resistance.</p></abstract><kwd-group><kwd>postbiotics</kwd><kwd>SCFAs</kwd><kwd>gastric cancer</kwd><kwd>doxorubicin</kwd><kwd>apoptosis</kwd><kwd>proteomics</kwd></kwd-group><funding-group><award-group><funding-source>Western Sydney University, Australia, through the PhD Research Training Program Scholarship</funding-source></award-group><award-group><funding-source>Research Support Program Fellowship</funding-source></award-group><funding-statement>This research received no external funding. We acknowledge the support of Western Sydney University, Australia, through the PhD Research Training Program Scholarship (R.E.) and the Research Support Program Fellowship (D.J.B.) to conduct this research.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-27-00362"><title>1. Introduction</title><p>Gastric cancer remains a major global health concern, ranked as the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related mortality as of 2020 [<xref rid="B1-ijms-27-00362" ref-type="bibr">1</xref>,<xref rid="B2-ijms-27-00362" ref-type="bibr">2</xref>]. The high mortality rate is largely due to late diagnosis, with many patients presenting with advanced disease [<xref rid="B2-ijms-27-00362" ref-type="bibr">2</xref>]. Despite progress in surgical techniques, recurrence following curative resection remains common, necessitating effective adjuvant treatment strategies [<xref rid="B3-ijms-27-00362" ref-type="bibr">3</xref>]. Chemotherapy plays a central role in the management of advanced or metastatic gastric cancer, either as neoadjuvant, adjuvant, or primary treatment [<xref rid="B4-ijms-27-00362" ref-type="bibr">4</xref>]. Doxorubicin (Dox), an anthracycline antibiotic, has long been used in combination chemotherapy regimens for gastric cancer [<xref rid="B5-ijms-27-00362" ref-type="bibr">5</xref>,<xref rid="B6-ijms-27-00362" ref-type="bibr">6</xref>,<xref rid="B7-ijms-27-00362" ref-type="bibr">7</xref>]. However, its clinical use is hampered by issues such as drug resistance and severe side effects, including cardiotoxicity, myelosuppression, and mucositis [<xref rid="B8-ijms-27-00362" ref-type="bibr">8</xref>,<xref rid="B9-ijms-27-00362" ref-type="bibr">9</xref>,<xref rid="B10-ijms-27-00362" ref-type="bibr">10</xref>]. Resistance to conventional chemotherapeutics like cisplatin and 5-fluorouracil (5-FU) has further complicated treatment, often leading to suboptimal clinical outcomes [<xref rid="B11-ijms-27-00362" ref-type="bibr">11</xref>]. Therefore, there is an urgent need to identify low-toxicity compounds with strong anticancer potential that could be integrated into new combination regimens to circumvent or mitigate drug resistance.</p><p>Diet plays a fundamental role in shaping the gut microbiota and, consequently, in maintaining host health and metabolic homeostasis [<xref rid="B12-ijms-27-00362" ref-type="bibr">12</xref>]. Diets rich in whole grains, legumes, fruits, and vegetables provide non-digestible carbohydrates (prebiotics) that reach the colon, where they are fermented by beneficial gut bacteria into health-promoting metabolites, including short-chain fatty acids (SCFAs) [<xref rid="B13-ijms-27-00362" ref-type="bibr">13</xref>]. Well-known fibre-fermenting bacteria such as <italic toggle="yes">Faecalibacterium prausnitzii</italic> and <italic toggle="yes">Eubacterium rectale</italic> produce SCFAs like acetate (A), propionate (P), and butyrate (B), which help maintain gut barrier integrity, modulate immune responses, and exhibit systemic anti-inflammatory effects [<xref rid="B13-ijms-27-00362" ref-type="bibr">13</xref>,<xref rid="B14-ijms-27-00362" ref-type="bibr">14</xref>,<xref rid="B15-ijms-27-00362" ref-type="bibr">15</xref>]. In contrast, Westernised diets low in fibre and high in saturated fats can reduce SCFA production by disrupting the balance of these beneficial microbial species, diminishing their protective effects and contributing to chronic disease risk [<xref rid="B12-ijms-27-00362" ref-type="bibr">12</xref>].</p><p>The gut microbiota contributes significantly to nutrient metabolism, immune modulation, and protection against pathogens [<xref rid="B16-ijms-27-00362" ref-type="bibr">16</xref>]. Beyond maintaining gut health, increasing evidence highlights its critical role as a modulator in cancer prevention and therapy [<xref rid="B17-ijms-27-00362" ref-type="bibr">17</xref>]. A key mechanism underlying these protective effects is the production of postbiotics, including SCFAs such as acetate, propionate, and butyrate [<xref rid="B18-ijms-27-00362" ref-type="bibr">18</xref>,<xref rid="B19-ijms-27-00362" ref-type="bibr">19</xref>]. These SCFAs exert both local and systemic actions relevant to cancer prevention and treatment by influencing cellular proliferation, apoptosis, oxidative stress, and immune pathways [<xref rid="B16-ijms-27-00362" ref-type="bibr">16</xref>,<xref rid="B17-ijms-27-00362" ref-type="bibr">17</xref>]. SCFAs are primarily generated in the large intestine through microbial fermentation of dietary fibres and are absorbed into systemic circulation, where they can exert effects beyond the gut [<xref rid="B20-ijms-27-00362" ref-type="bibr">20</xref>]. Their intestinal concentrations vary along the colon, generally ranging from 70&#8211;140 mM in the proximal region to 20&#8211;70 mM distally, with total SCFA levels in the colon typically falling between 20 and 140 mM [<xref rid="B20-ijms-27-00362" ref-type="bibr">20</xref>]. Butyrate, in particular, is well documented for its antiproliferative and proapoptotic properties in various cancers through mechanisms such as histone deacetylase (HDAC) inhibition, reactive oxygen species (ROS) modulation, and regulation of apoptotic signalling pathways [<xref rid="B21-ijms-27-00362" ref-type="bibr">21</xref>,<xref rid="B22-ijms-27-00362" ref-type="bibr">22</xref>]. Propionate and acetate have also demonstrated distinct anticancer activities, including modulation of the NF-&#954;B and Wnt/&#946;-catenin pathways and interference with cancer cell metabolism [<xref rid="B23-ijms-27-00362" ref-type="bibr">23</xref>,<xref rid="B24-ijms-27-00362" ref-type="bibr">24</xref>].</p><p>Sodium butyrate has demonstrated the ability to enhance the effectiveness of various chemotherapeutic agents [<xref rid="B25-ijms-27-00362" ref-type="bibr">25</xref>,<xref rid="B26-ijms-27-00362" ref-type="bibr">26</xref>,<xref rid="B27-ijms-27-00362" ref-type="bibr">27</xref>,<xref rid="B28-ijms-27-00362" ref-type="bibr">28</xref>,<xref rid="B29-ijms-27-00362" ref-type="bibr">29</xref>,<xref rid="B30-ijms-27-00362" ref-type="bibr">30</xref>]. It has been reported to sensitize tumour cells to docetaxel and, when used alongside cisplatin, significantly increases apoptosis in gastric cancer cells through activation of the mitochondrial apoptotic pathway [<xref rid="B25-ijms-27-00362" ref-type="bibr">25</xref>,<xref rid="B26-ijms-27-00362" ref-type="bibr">26</xref>]. B also improves the impact of 5-FU in colon cancer cells by further disrupting DNA synthesis [<xref rid="B27-ijms-27-00362" ref-type="bibr">27</xref>]. In lung cancer, B administered prior to paclitaxel treatment helped restore gut microbiota balance, food intake, and intestinal barrier function, thereby reducing treatment-related side effects [<xref rid="B28-ijms-27-00362" ref-type="bibr">28</xref>]. In bladder cancer, co-treatment with B and cisplatin showed synergistic anticancer effects by promoting G1-phase cell cycle arrest and apoptosis through the regulation of proteins such as p21, p27, TRADD, and procaspase-2 [<xref rid="B29-ijms-27-00362" ref-type="bibr">29</xref>]. Additionally, propionate has been shown to enhance cisplatin&#8217;s cytotoxicity in liver cancer cells by modulating GPR41 signalling pathways [<xref rid="B30-ijms-27-00362" ref-type="bibr">30</xref>].</p><p>In a study conducted in our lab, B synergised with dexamethasone to enhance antiproliferative effects against AGS gastric cancer cells [<xref rid="B31-ijms-27-00362" ref-type="bibr">31</xref>]. A follow-up study evaluated combinations of SCFAs (AP, AB, PB, APB) and their co-treatment with Dex (APB+Dex) [<xref rid="B32-ijms-27-00362" ref-type="bibr">32</xref>]. The APB+Dex combination exhibited strong synergistic interactions, targeting multiple tumour-promoting mechanisms, including the disruption of redox balance and the induction of apoptosis. Encouraged by these promising synergistic interactions between SCFAs and chemotherapeutic or immunotherapeutic agents, the current study further investigated the effects of APB, Dox, and their combination (APB+Dox) on AGS gastric adenocarcinoma cells. This novel combination aims to evaluate enhanced safety profile, induction of apoptosis, modulation of oxidative stress, and proteomic reprogramming, offering potential insights into more effective and safer therapeutic strategies for gastric cancer.</p></sec><sec sec-type="results" id="sec2-ijms-27-00362"><title>2. Results and Discussion</title><sec id="sec2dot1-ijms-27-00362"><title>2.1. Antiproliferative Activity of SCFA Combinations, Dox, and Their Combination Against AGS Adenocarcinoma Cells</title><p>Magnesium acetate, sodium propionate, and sodium butyrate were used to prepare the APB mixture, reflecting the physiologically relevant salt forms of SCFAs present in the colonic lumen [<xref rid="B20-ijms-27-00362" ref-type="bibr">20</xref>]. The concentration range (93.75&#8211;3000 &#956;g/mL) captures both physiologically relevant exposures (0.8&#8211;10 mM) and supra-physiological conditions (up to ~26.5 mM total SCFAs) frequently used in mechanistic studies to model pharmacological exposure [<xref rid="B20-ijms-27-00362" ref-type="bibr">20</xref>]. At the same time, our dosing strategy reflects established in vitro practice. Numerous cancer studies have applied SCFAs across 0.5&#8211;10 mM and reported dose-dependent antiproliferative and proapoptotic effects. For instance, butyrate and propionate have demonstrated growth inhibition in gastric and breast cancer cells, with IC<sub>50</sub> values of ~1.3 mM (B) and ~4.5 mM (P), respectively, and apoptosis induction at higher millimolar concentrations [<xref rid="B33-ijms-27-00362" ref-type="bibr">33</xref>,<xref rid="B34-ijms-27-00362" ref-type="bibr">34</xref>]</p><p>In the current study, APB alone achieved 95.65 &#177; 7.90% inhibition at 3000 &#956;g/mL (<italic toggle="yes">p</italic> &lt; 0.05) with an IC<sub>50</sub> of 568.33 &#177; 82.56 &#956;g/mL. Dox alone (<italic toggle="yes">p</italic> &lt; 0.05) produced 73.51 &#177; 5.16% inhibition at 0.54 &#956;g/mL with an IC<sub>50</sub> of 0.22 &#177; 0.04 &#956;g/mL (<xref rid="ijms-27-00362-t001" ref-type="table">Table 1</xref>). The combination of APB and Dox (<italic toggle="yes">p</italic> &lt; 0.05) resulted in 103.46 &#177; 2.24% inhibition at 3000 &#956;g/mL APB + 0.27 &#956;g/mL Dox and an IC<sub>50</sub> of 512.80 &#177; 18.37 &#956;g/mL (<xref rid="ijms-27-00362-t001" ref-type="table">Table 1</xref>). In normal Hs 738.St/Int human intestinal cells, Dox alone reduced viability to 38.37 &#177; 7.01% at 0.54 &#956;g/mL. APB alone maintained 76.59 &#177; 8.56% viability, and the APB+Dox combination at 3000 &#956;g/mL + 0.27 &#956;g/mL achieved 64.12 &#177; 8.76% viability. At 1500 &#956;g/mL APB + 0.136 &#956;g/mL Dox, viability was 92.42 &#177; 10.66%, compared with 79.67 &#177; 8.16% for APB alone and 68.52 &#177; 7.51% for Dox alone. At concentrations &#8804; 750 &#956;g/mL APB, combination treatments produced viability values exceeding 100%, with a maximum of 112.90 &#177; 11.32% at 187.5 &#956;g/mL APB + 0.017 &#956;g/mL Dox (<xref rid="ijms-27-00362-t001" ref-type="table">Table 1</xref>).</p><p>Notably, the improved viability of normal intestinal cells observed with the APB+Dox combination compared to Dox alone suggests a potential protective or toxicity-modulating effect of APB. This finding is consistent with previous reports indicating that SCFAs, particularly butyrate and propionate, can attenuate chemotherapy-induced toxicity by preserving mitochondrial function, reducing oxidative stress, and modulating inflammatory responses [<xref rid="B35-ijms-27-00362" ref-type="bibr">35</xref>]. Such effects may be relevant to mitigating known dose-limiting side effects of Dox, including cardiotoxicity and gastrointestinal injury, as demonstrated in preclinical models [<xref rid="B36-ijms-27-00362" ref-type="bibr">36</xref>].</p></sec><sec id="sec2dot2-ijms-27-00362"><title>2.2. Synergistic Potential of APB with Dox Against the AGS Cells</title><p>The potential synergistic effects of APB and Dox combination on AGS gastric adenocarcinoma cells were analysed using the CI model [<xref rid="B37-ijms-27-00362" ref-type="bibr">37</xref>]. The APB+Dox combination exhibited a pronounced synergistic effect, reflected in a CI value of 0.61 at the IC<sub>50</sub> level, further confirming the potential of this combination to enhance therapeutic efficacy against gastric cancer (<xref rid="ijms-27-00362-f001" ref-type="fig">Figure 1</xref>). The IC<sub>75</sub> (0.34), IC<sub>90</sub> (0.19), and IC<sub>95</sub> (0.13) values also showed reduced CI values, indicating that the synergy persists across a range of concentrations. These findings suggest that the inclusion of APB combinations with established chemotherapeutic agents like Dox significantly enhance the inhibitory effects on AGS gastric adenocarcinoma cells.</p></sec><sec id="sec2dot3-ijms-27-00362"><title>2.3. Proteomics Study of the AGS Cells Treated with the Synergistic Combination vs. Monotreatments</title><p>Following the promising cell studies and synergy studies, proteomic analysis was conducted in AGS cells after treatment with Dox (compared to the untreated control), and with the APB+Dox combination compared to Dox and APB monotherapies.</p><sec id="sec2dot3dot1-ijms-27-00362"><title>2.3.1. Enrichment Analyses of Differentially Expressed Proteins (DEPs) in Dox-Treated AGS Cells Compared to the Control Untreated Cells</title><p>Dox is a widely used anthracycline chemotherapeutic that exerts its anticancer activity primarily through DNA intercalation, inhibition of topoisomerase II, and generation of ROS, which collectively lead to DNA damage and activation of apoptotic pathways [<xref rid="B36-ijms-27-00362" ref-type="bibr">36</xref>]. The current study represents one of the first comprehensive analyses of dysregulated proteins in AGS gastric adenocarcinoma cells following treatment with Dox or its combination with APB.</p><p>The volcano plot of Dox treatment versus untreated control in AGS cells highlights a range of significantly dysregulated proteins, with several key players implicated in anticancer mechanisms (<xref rid="ijms-27-00362-f002" ref-type="fig">Figure 2</xref>A). Among the most upregulated genes is <italic toggle="yes">TP53</italic>, a pivotal tumour suppressor involved in cell cycle arrest, DNA repair, and apoptosis, whose activation reinforces Dox&#8217;s classical cytotoxic role in cancer therapy [<xref rid="B38-ijms-27-00362" ref-type="bibr">38</xref>]. HSD11B2, also upregulated, modulates glucocorticoid metabolism and may influence stress hormone signalling within the tumour microenvironment [<xref rid="B39-ijms-27-00362" ref-type="bibr">39</xref>]. IKBIP and CEBPB were both found to be elevated in expression, supporting their known roles in regulating apoptosis and inflammatory signalling pathways that suppress tumour survival [<xref rid="B40-ijms-27-00362" ref-type="bibr">40</xref>]. ARG2 showed increased expression and has been associated with immune modulation and tumour progression, while ENDOG, another upregulated protein, is a mitochondrial nuclease involved in caspase-independent cell death [<xref rid="B41-ijms-27-00362" ref-type="bibr">41</xref>,<xref rid="B42-ijms-27-00362" ref-type="bibr">42</xref>].</p><p>On the downregulated end, several ribosome biogenesis and RNA processing genes are markedly suppressed. For example, <italic toggle="yes">RIOK2</italic>, <italic toggle="yes">RPL7L1</italic>, <italic toggle="yes">RRP7A</italic>, <italic toggle="yes">NOP14</italic>, <italic toggle="yes">NSA2</italic>, and <italic toggle="yes">UTP6</italic> are associated with ribosomal RNA synthesis and maturation [<xref rid="B43-ijms-27-00362" ref-type="bibr">43</xref>]. Their repression may impair protein translation, contributing to reduced tumour cell proliferation. <italic toggle="yes">DDX21</italic> and <italic toggle="yes">DDX56</italic>, both DEAD-box RNA helicases, are involved in transcriptional regulation and ribosome assembly, and their downregulation may further dampen the biosynthetic capacity of gastric cancer cells [<xref rid="B44-ijms-27-00362" ref-type="bibr">44</xref>]. Suppression of <italic toggle="yes">MRFAP1</italic>, which is linked to chromatin organisation and DNA replication, may enhance DNA damage sensitivity in the presence of Dox [<xref rid="B45-ijms-27-00362" ref-type="bibr">45</xref>].</p><p>The graphical summary (<xref rid="ijms-27-00362-f002" ref-type="fig">Figure 2</xref>B) shows that Dox triggered tumour-suppressive signalling, metabolic and immune reprogramming, and inhibition of stemness-related gene expression. Key regulatory hubs such as <italic toggle="yes">TP53</italic>, <italic toggle="yes">MYC</italic>, and <italic toggle="yes">TFDP1</italic> orchestrate these changes across core biological processes, including enhanced cell death, lipid oxidation, and transcriptional regulation [<xref rid="B38-ijms-27-00362" ref-type="bibr">38</xref>,<xref rid="B46-ijms-27-00362" ref-type="bibr">46</xref>]. These insights suggest that Dox did more than induce apoptosis, it also reconfigured the cellular state of AGS cells, potentially weakening their proliferative and adaptive capacities and offering opportunities to overcome therapeutic resistance. A key feature of Dox&#8217;s action in AGS cells is the activation of <italic toggle="yes">TP53</italic>-mediated tumour suppression and the repression of oncogenes such as <italic toggle="yes">MYC</italic>, contributing to reduced cell viability and heightened apoptotic signalling. In parallel, modulation of lipid metabolism genes like <italic toggle="yes">KLF15</italic> and <italic toggle="yes">ESRRA</italic> points to a Dox-induced oxidative stress phenotype, known to provoke mitochondrial dysfunction and DNA damage in gastric cancer cells [<xref rid="B47-ijms-27-00362" ref-type="bibr">47</xref>].</p><p>Dox also stimulated immune-related genes, notably <italic toggle="yes">IFNB1</italic>, reflecting activation of antiviral and inflammatory pathways that could enhance tumour immunogenicity [<xref rid="B47-ijms-27-00362" ref-type="bibr">47</xref>]. Furthermore, the repression of stemness-associated genes such as <italic toggle="yes">POU5F1</italic> and <italic toggle="yes">EFNA5</italic> suggests an anticancer stem cell effect, with implications for limiting recurrence and resistance [<xref rid="B48-ijms-27-00362" ref-type="bibr">48</xref>].</p><p>Among the most significantly inhibited pathways is the &#8220;Major pathway of rRNA processing in the nucleolus and cytosol&#8221;, alongside suppression of ribosomal protein synthesis and translation-associated machinery (<xref rid="app1-ijms-27-00362" ref-type="app">Figure S1</xref>). These changes suggest that Dox markedly interfered with ribosome biogenesis and function, a process often hijacked in cancer to support uncontrolled protein synthesis and proliferation. In addition to ribosomal dysregulation, Dox significantly inhibited DNA-related pathways, including DNA replication, repair, and chromatin remodelling (<xref rid="app1-ijms-27-00362" ref-type="app">Figure S1</xref>). These disruptions reflected Dox&#8217;s known mechanism of action as a DNA intercalator and topoisomerase II inhibitor, inducing double-strand breaks and genomic instability in cancer cells. Moreover, suppression of the cell cycle, particularly the G<sub>2</sub>/M checkpoint and mitotic entry, reinforced Dox&#8217;s antiproliferative impact.</p><list list-type="simple"><list-item><p>Ribosomal Protein Regulation</p></list-item></list><p>Dox treatment resulted in the downregulation of multiple ribosomal proteins (RP), such as RPSA (log2FC = &#8722;0.70), RPL6 (log2FC = &#8722;0.73), RPL10 (log2FC = &#8722;0.64), RPL23 (log2FC = &#8722;0.62), RPS3A (log2FC = &#8722;0.59), RPS6 (log2FC = &#8722;0.59), RPS27 (log2FC = &#8722;0.58), RPL7A (log2FC = &#8722;0.60), RPL13A (log2FC = &#8722;1.04), RPL7L1 (log2FC = &#8722;3.12), and others (log2FC ranging from &#8722;0.58 to &#8722;3.12), which indicates that Dox suppressed ribosomal function in AGS cells [<xref rid="B49-ijms-27-00362" ref-type="bibr">49</xref>,<xref rid="B50-ijms-27-00362" ref-type="bibr">50</xref>,<xref rid="B51-ijms-27-00362" ref-type="bibr">51</xref>,<xref rid="B52-ijms-27-00362" ref-type="bibr">52</xref>,<xref rid="B53-ijms-27-00362" ref-type="bibr">53</xref>,<xref rid="B54-ijms-27-00362" ref-type="bibr">54</xref>] (<xref rid="ijms-27-00362-f003" ref-type="fig">Figure 3</xref>). These proteins are essential for various aspects of ribosome function, including protein synthesis, ribosome assembly, and translational regulation. Many of the ribosomal proteins affected by Dox, such as RPL6 (log2FC = &#8722;0.73), RPL13A (log2FC = &#8722;1.04), and RPL39 (log2FC = &#8722;0.68), have been linked to progression in gastric cancer [<xref rid="B55-ijms-27-00362" ref-type="bibr">55</xref>,<xref rid="B56-ijms-27-00362" ref-type="bibr">56</xref>,<xref rid="B57-ijms-27-00362" ref-type="bibr">57</xref>]. For example, RPL6 and RPL10 (log2FC = &#8722;0.64) are associated with gastric and colorectal cancers, and RPL23 (log2FC = &#8722;0.62) is known to promote tumorigenesis [<xref rid="B55-ijms-27-00362" ref-type="bibr">55</xref>,<xref rid="B58-ijms-27-00362" ref-type="bibr">58</xref>,<xref rid="B59-ijms-27-00362" ref-type="bibr">59</xref>]. The downregulation of these ribosomal proteins could be interpreted as a therapeutic effect of Dox, potentially slowing down cancer cell proliferation and invasion by interfering with the synthesis of key proteins involved in tumour progression (<xref rid="ijms-27-00362-f003" ref-type="fig">Figure 3</xref>). Other ribosomal proteins, such as RPS3A (log2FC = &#8722;0.59), RPS6 (log2FC = &#8722;0.59), and RPL13A (log2FC = &#8722;1.04), are not only involved in ribosome function but also have roles in cancer cell proliferation and metastasis [<xref rid="B50-ijms-27-00362" ref-type="bibr">50</xref>,<xref rid="B53-ijms-27-00362" ref-type="bibr">53</xref>]. Specifically, RPS6 (log2FC = &#8722;0.59), which is involved in mTOR signalling, is often activated in gastric cancer, and its downregulation by Dox might impact this critical pathway, potentially reducing cancer cell growth and metastasis [<xref rid="B60-ijms-27-00362" ref-type="bibr">60</xref>,<xref rid="B61-ijms-27-00362" ref-type="bibr">61</xref>].</p><p>Some of the genes affected by Dox, such as <italic toggle="yes">RPS27A</italic> (log2FC = &#8722;0.63), <italic toggle="yes">RPL38</italic> (log2FC = &#8722;0.65), and <italic toggle="yes">RPL14</italic> (log2FC = &#8722;0.77), are involved in ribosome stability and function, and their dysregulation is associated with cancer progression and metastasis [<xref rid="B51-ijms-27-00362" ref-type="bibr">51</xref>,<xref rid="B62-ijms-27-00362" ref-type="bibr">62</xref>,<xref rid="B63-ijms-27-00362" ref-type="bibr">63</xref>]. Additionally, serine/threonine-protein kinase SMG enzymes were reported to decrease by a DNA damage inducer, such as Dox [<xref rid="B64-ijms-27-00362" ref-type="bibr">64</xref>]. In the current study, genes such as SMG1 (log2FC = &#8722;0.61), SMG6 (log2FC = &#8722;0.80), and SMG7 (log2FC = &#8722;0.92), which are involved in nonsense-mediated mRNA decay (a component of the DNA repair response), show downregulation in response to Dox. This suggests that the drug may influence the cellular DNA damage response in a way that could further reduce the ability of cancer cells to proliferate and survive under stressful conditions.</p><p>The downregulation of key ribosomal proteins and associated biogenesis factors&#8212;such as RIOK2, UTP6, NSA2, and WDR46&#8212;indicates that Dox significantly impairs ribosome maturation and assembly (<xref rid="ijms-27-00362-f003" ref-type="fig">Figure 3</xref>) [<xref rid="B65-ijms-27-00362" ref-type="bibr">65</xref>]. RIOK2, for example, is critical for the late-stage maturation of the 40S ribosomal subunit. Its marked downregulation (log2FC = &#8722;4.73) by Dox potentially inhibited the formation of functional ribosomes, reducing the translational capacity of cancer cells [<xref rid="B65-ijms-27-00362" ref-type="bibr">65</xref>]. Similarly, UTP6 (log2FC = &#8722;3.99) and UTP14A (log2FC = &#8722;3.24), integral components of the small subunit processome, are involved in pre-rRNA processing [<xref rid="B66-ijms-27-00362" ref-type="bibr">66</xref>]. Their suppression disrupts ribosomal RNA synthesis, thereby limiting ribosome production. Downregulation of UTP6 and UTP14A is associated with drug resistance and poor prognosis in gastric cancer [<xref rid="B67-ijms-27-00362" ref-type="bibr">67</xref>,<xref rid="B68-ijms-27-00362" ref-type="bibr">68</xref>]. Combination therapies (such as APB+Dox) targeting complementary pathways may help overcome resistance.</p><p>The downregulation of ribosomal proteins such as DDX56 (log2FC = &#8722;3.12) and RRP7A (log2FC = &#8722;2.83) underscored Dox&#8217;s broad impact on ribosome biogenesis [<xref rid="B43-ijms-27-00362" ref-type="bibr">43</xref>,<xref rid="B69-ijms-27-00362" ref-type="bibr">69</xref>]. These proteins are crucial for various stages of ribosomal assembly, and their inhibition by Dox suggests a comprehensive disruption of this process. The suppression of proteins like WDR46 (log2FC = &#8722;3.27) and NSA2 (log2FC = &#8722;3.61) highlighted Dox&#8217;s potential ability to induce ribosomal stress, a state that sensitizes cancer cells to apoptosis [<xref rid="B70-ijms-27-00362" ref-type="bibr">70</xref>,<xref rid="B71-ijms-27-00362" ref-type="bibr">71</xref>]. WDR46, a scaffold protein essential for nucleolar structure and ribosomal RNA processing, is crucial for maintaining the nucleolus, a hub of ribosome biogenesis [<xref rid="B70-ijms-27-00362" ref-type="bibr">70</xref>]. Its downregulation disrupts nucleolar integrity, a phenomenon that has been linked to the activation of p53-mediated apoptotic pathways [<xref rid="B72-ijms-27-00362" ref-type="bibr">72</xref>]. Similarly, the inhibition of NSA2, which facilitates 60S ribosomal subunit assembly, further compromises ribosomal function, halting protein synthesis and cancer cell growth [<xref rid="B73-ijms-27-00362" ref-type="bibr">73</xref>].</p><list list-type="simple"><list-item><p>DNA-related processes</p></list-item></list><p>Dox also impacted DNA-related processes in AGS gastric cancer cells, targeting key proteins involved in DNA repair, replication, and stability. Its effects were evident in multiple pathways that regulate DNA damage response (DDR), replication fork dynamics, and chromatin stability, collectively contributing to its anticancer efficacy (<xref rid="ijms-27-00362-f003" ref-type="fig">Figure 3</xref>). Among the DDR (DNA damage response) proteins, Poly(ADP-ribose) polymerases (PARPs) such as PARP2 (log2FC = &#8722;1.43), PARP4 (log2FC = &#8722;1.04), and PARP12 (log2FC = &#8722;0.94), all of which are central to DNA repair mechanisms, showed significant downregulation. Dox is known to impair DDR by targeting key genes, such as <italic toggle="yes">PARPs</italic>, a crucial player in DNA repair that interacts with DNA strand breaks [<xref rid="B74-ijms-27-00362" ref-type="bibr">74</xref>]. <italic toggle="yes">BRCA</italic>-encoded protein is crucial for the homologous recombination repair mechanism, which is vital for repairing double-strand breaks caused by Dox [<xref rid="B75-ijms-27-00362" ref-type="bibr">75</xref>]. The loss of BRCA1 expression has been shown to enhance resistance to Dox in other cancer models, where BRCA1 deficiency triggers resistance mechanisms [<xref rid="B75-ijms-27-00362" ref-type="bibr">75</xref>]. The downregulation of <italic toggle="yes">BRCA1</italic> (log2FC = &#8722;0.80) in AGS cells treated with Dox suggests that the DNA damage response (DDR) pathway may be compromised, impairing the cells&#8217; ability to repair DNA effectively. The suppression of these genes potentially compromised the recombination repair, a vital pathway for repairing DNA double-strand breaks. In addition, the reduction in <italic toggle="yes">RAD51</italic> (log2FC = &#8722;0.67) further hindered this repair process, leading to increased genomic instability and heightened susceptibility to apoptosis in cancer cells [<xref rid="B76-ijms-27-00362" ref-type="bibr">76</xref>]. Interestingly, <italic toggle="yes">XPC</italic> (log2FC = 1.13), a gene involved in nucleotide excision repair, was upregulated, suggesting a cellular attempt to counteract the widespread DNA damage. This is in line with a previous study demonstrating the overexpression of <italic toggle="yes">XPC</italic> gene in Dox-treated cells [<xref rid="B77-ijms-27-00362" ref-type="bibr">77</xref>].</p><p>Dox also impacted proteins critical for maintaining DNA metabolism and chromosomal stability. Telomeric repeat-binding factor 1 (TERF1) is a key protein within the telomere complex essential in mediating the interactions between telomeres in mammalian cells [<xref rid="B78-ijms-27-00362" ref-type="bibr">78</xref>]. It helps regulate telomere length and stability by binding to the telomeric DNA repeats, thereby facilitating the structural integrity of the telomeres [<xref rid="B79-ijms-27-00362" ref-type="bibr">79</xref>]. The observed downregulation of <italic toggle="yes">TERF1</italic>-encoded protein (log2FC = &#8722;1.22) suggests potential telomere destabilization, which may contribute to genomic instability. In addition, the reduced expression of replication fork-associated genes, such as <italic toggle="yes">SMARCAL1</italic> (log2FC = &#8722;0.68) and <italic toggle="yes">SMARCAD1</italic> (log2FC = &#8722;0.71), was aligned with disruptions in DNA replication fidelity, exacerbating genomic instability [<xref rid="B80-ijms-27-00362" ref-type="bibr">80</xref>]. The significant downregulation of <italic toggle="yes">SETD2</italic> (log2FC = &#8722;2.02), responsible for histone <italic toggle="yes">H3K36</italic> methylation, may further impair chromatin remodelling and repair, weakening the cell&#8217;s ability to maintain genomic integrity [<xref rid="B81-ijms-27-00362" ref-type="bibr">81</xref>]. <italic toggle="yes">SETD2</italic> mutations contribute to resistance to Dox by impairing the DDR, weakening the apoptotic response to chemotherapy [<xref rid="B82-ijms-27-00362" ref-type="bibr">82</xref>]. In gastric cancer, the downregulation of proteins like MUC1 (log2FC = &#8722;0.68), AXIN2 (log2FC = &#8722;1.50), and MGMT (log2FC = &#8722;0.77) potentially indicate the disruption of DNA damage response and signalling pathways, with Dox having a broad impact on these processes [<xref rid="B83-ijms-27-00362" ref-type="bibr">83</xref>,<xref rid="B84-ijms-27-00362" ref-type="bibr">84</xref>,<xref rid="B85-ijms-27-00362" ref-type="bibr">85</xref>,<xref rid="B86-ijms-27-00362" ref-type="bibr">86</xref>]. While MGMT is more closely associated with alkylating agents, its downregulation in this context could reflect an indirect effect [<xref rid="B85-ijms-27-00362" ref-type="bibr">85</xref>]. Additionally, the suppression of FANCG (log2FC = &#8722;1.99), a key player in the Fanconi anaemia pathway, indicates a probable disruption of DNA repair mechanisms in the AGS gastric cancer cells, contributing to increased DNA damage [<xref rid="B87-ijms-27-00362" ref-type="bibr">87</xref>].</p><p>SOX9, a transcription factor crucial for cartilage formation and stem cell regulation, also plays roles in cellular responses to DNA damage [<xref rid="B88-ijms-27-00362" ref-type="bibr">88</xref>]. STAT6, another transcription factor, is involved in the regulation of immune responses and inflammation, which may be critical in response to Dox-induced cellular stress [<xref rid="B89-ijms-27-00362" ref-type="bibr">89</xref>]. The downregulation of SOX9 (log2FC = &#8722;1.33) and STAT6 (log2FC = &#8722;0.84) suggests disruptions in transcriptional regulation related to DNA repair and inflammation [<xref rid="B88-ijms-27-00362" ref-type="bibr">88</xref>,<xref rid="B89-ijms-27-00362" ref-type="bibr">89</xref>]. Their downregulation could impact cellular responses to DNA damage and inflammatory signals, which aligns with the observed effects of Dox treatment. Additionally, the upregulation of <italic toggle="yes">SYVN1</italic> (log2FC = 1.30), a gene involved in the cellular stress response and protein degradation, indicates an active, though insufficient, compensatory mechanism to mitigate the damage [<xref rid="B90-ijms-27-00362" ref-type="bibr">90</xref>]. <italic toggle="yes">SYVN1</italic>&#8217;s role in responding to DNA-damage-induced stress further reflects the cell&#8217;s attempt to cope with Dox-induced damage, but the response may not be enough to overcome the widespread effects of the drug [<xref rid="B90-ijms-27-00362" ref-type="bibr">90</xref>]. Finally, Dox modulated proteins linked to DNA replication complexes and chromatin remodelling. While GINS2 (log2FC = 1.46) and GINS4 (log2FC = 1.41) were upregulated, potentially reflecting compensatory mechanisms to sustain replication, the suppression of histone methyltransferases such as ASH1L (log2FC = &#8722;1.26) potentially limited the capacity for chromatin repair and transcription regulation [<xref rid="B91-ijms-27-00362" ref-type="bibr">91</xref>,<xref rid="B92-ijms-27-00362" ref-type="bibr">92</xref>].</p><list list-type="simple"><list-item><p>Cell Cycle</p></list-item></list><p>Dox significantly impacted the cell cycle in AGS gastric cancer cells by targeting key regulatory pathways and proteins involved in cell cycle progression. From the data provided, Dox induced disruptions at multiple checkpoints, particularly within the G<sub>1</sub>/S and G<sub>2</sub>/M phases, thereby promoting cell cycle arrest.</p><list list-type="simple"><list-item><p><italic toggle="yes">G</italic><sub>1</sub>/<italic toggle="yes">S Phase Arrest</italic></p></list-item></list><p>Dox&#8217;s action began at the G<sub>1</sub>/S transition, disrupting the progression into the S phase by downregulating critical cyclins and CDKs that control the checkpoint. Key proteins affected include CCND1 (log2FC = &#8722;1.90), CDK4 (log2FC = &#8722;1.34), and CDK6 (log2FC = &#8722;0.77), leading to reduced phosphorylation of Rb protein and failure to activate E2F transcription factors [<xref rid="B93-ijms-27-00362" ref-type="bibr">93</xref>,<xref rid="B94-ijms-27-00362" ref-type="bibr">94</xref>]. The suppression of E2F4 (log2FC = &#8722;1.71) further inhibited the transcription of <italic toggle="yes">S</italic>-phase related proteins, compounding the block at this checkpoint (<xref rid="ijms-27-00362-f003" ref-type="fig">Figure 3</xref>) [<xref rid="B95-ijms-27-00362" ref-type="bibr">95</xref>]. Moreover, the upregulation of TP53 (log2FC = 2.94) reinforced this arrest through the activation of p21 (CDKN1A), a cyclin-dependent kinase inhibitor (CDKI), which binds to and inhibits CDK4/6 activity [<xref rid="B96-ijms-27-00362" ref-type="bibr">96</xref>]. This halted cell cycle progression and allowed cells to initiate DNA damage repair or apoptosis [<xref rid="B96-ijms-27-00362" ref-type="bibr">96</xref>]. The overall inhibition at this stage potentially prevented AGS cells from replicating damaged DNA, a hallmark of effective anticancer action. Interestingly, despite the suppression of key G1/S drivers, the upregulation of CCND3 (log2FC = 1.03) and CCNE1 (log2FC = 1.58) suggests that some compensatory mechanisms might be activated in response to Dox-induced stress [<xref rid="B97-ijms-27-00362" ref-type="bibr">97</xref>]. However, these attempts were insufficient to overcome the dominant inhibitory effects mediated by Rb and p53.</p><list list-type="simple"><list-item><p>
<italic toggle="yes">S Phase Disruption</italic>
</p></list-item></list><p>While the G<sub>1</sub>/S arrest was prominent, Dox also impacted cells that entered the S phase. The downregulation of replication factors like MCM10 (log2FC = &#8722;0.80) and proteins associated with replication origin licensing disrupted DNA replication initiation [<xref rid="B98-ijms-27-00362" ref-type="bibr">98</xref>]. The reduced expression of PCNA (log2FC = 0.68), a critical replication clamp protein, further hampered replication fork progression [<xref rid="B99-ijms-27-00362" ref-type="bibr">99</xref>]. These disruptions created replication stress, which is exacerbated by the suppression of checkpoint kinases CHEK1 (log2FC = &#8722;1.11) and CHEK2 (log2FC = &#8722;1.07) [<xref rid="B100-ijms-27-00362" ref-type="bibr">100</xref>]. These kinases are vital for detecting and repairing stalled replication forks [<xref rid="B100-ijms-27-00362" ref-type="bibr">100</xref>]. Their downregulation allows replication stress to persist, accumulating DNA damage and driving cells toward apoptosis instead of completing the S phase.</p><list list-type="simple"><list-item><p><italic toggle="yes">G</italic><sub>2</sub>/<italic toggle="yes">M Phase Arrest</italic></p></list-item></list><p>Dox may also profoundly affect the G<sub>2</sub>/M checkpoint, preventing cells with damaged DNA from entering mitosis. The downregulation of PLK1 (log2FC = &#8722;0.73), a key regulator of mitotic entry and spindle assembly, disrupted mitotic initiation [<xref rid="B101-ijms-27-00362" ref-type="bibr">101</xref>]. Similarly, the suppression of MAD2L2 (log2FC = &#8722;1.10) and BUB1 (log2FC = &#8722;0.88) interfered with spindle checkpoint signalling, leading to improper chromosomal alignment and segregation [<xref rid="B102-ijms-27-00362" ref-type="bibr">102</xref>,<xref rid="B103-ijms-27-00362" ref-type="bibr">103</xref>]. Separase regulators like ANAPC7 (log2FC = &#8722;0.77), along with the upregulation of PTTG1 (Securin) (log2FC = 0.90), reflected a broader disruption of chromosome segregation machinery [<xref rid="B104-ijms-27-00362" ref-type="bibr">104</xref>,<xref rid="B105-ijms-27-00362" ref-type="bibr">105</xref>]. Overexpression of PTTG1 in normal human fibroblasts activates the DNA damage response pathway, leading to p53-dependent cell cycle arrest [<xref rid="B105-ijms-27-00362" ref-type="bibr">105</xref>].</p><list list-type="simple"><list-item><p>
<italic toggle="yes">Mitotic phase</italic>
</p></list-item></list><p>Mitotic disruption caused by Dox culminates in mitotic phase arrest, a process characterized by cell death following defective mitosis. The <italic toggle="yes">TP53</italic> gene, which encodes the p53 protein, plays a central role in cell cycle arrest by stopping the cell cycle and preventing the spread of DNA-damaged cells [<xref rid="B106-ijms-27-00362" ref-type="bibr">106</xref>]. Upregulation of <italic toggle="yes">TP53</italic> (log2FC = 2.94) plays a central role in this outcome by enforcing checkpoints and initiating apoptosis. Furthermore, the observed downregulation of NDC80 (log2FC = &#8722;1.08), a kinetochore complex component, potentially disrupted microtubule attachment and chromosome alignment, further impairing mitotic fidelity [<xref rid="B107-ijms-27-00362" ref-type="bibr">107</xref>]. Proteins like ESPL1 (Separin) (log2FC = 0.81) and other regulators of chromosome segregation were affected in a way that enhanced chromosomal instability, creating a lethal environment for cancer cells [<xref rid="B108-ijms-27-00362" ref-type="bibr">108</xref>].</p></sec><sec id="sec2dot3dot2-ijms-27-00362"><title>2.3.2. Enriched Pathways Using DEPs of APB+Dox Combination-Treated AGS Cells vs. Monotreatments</title><p><xref rid="app1-ijms-27-00362" ref-type="app">Figure S2</xref> illustrates the machine-learning-based prediction of molecular effects on the malignant neoplasm of the aerodigestive tract signalling pathway, highlighting the impact of APB+Dox treatment compared to the control (<xref rid="app1-ijms-27-00362" ref-type="app">Figure S2</xref>). This systems-level prediction corresponds closely with proteomic changes identified in the volcano plot (<xref rid="ijms-27-00362-f004" ref-type="fig">Figure 4</xref>A), which compares APB+Dox treatment to individual APB and Dox monotherapies and highlights several differentially expressed genes potentially relevant to the anticancer activity of the combination in AGS gastric adenocarcinoma cells. Notably, several downregulated genes, such as <italic toggle="yes">HLA-F</italic>, <italic toggle="yes">TRIAP1</italic>, <italic toggle="yes">ENTPD8</italic>, <italic toggle="yes">TMBIM6</italic>, and <italic toggle="yes">TMSB10</italic>, are known to play roles in cell survival, mitochondrial integrity, and antiapoptotic processes. <italic toggle="yes">HLA-F</italic>, a non-classical class I molecule, is implicated in cancer, often upregulated in various types of tumours [<xref rid="B109-ijms-27-00362" ref-type="bibr">109</xref>,<xref rid="B110-ijms-27-00362" ref-type="bibr">110</xref>,<xref rid="B111-ijms-27-00362" ref-type="bibr">111</xref>]. It can be found in cancer cells, potentially allowing them to evade immune surveillance and suppress antitumour immune responses [<xref rid="B109-ijms-27-00362" ref-type="bibr">109</xref>]. Additionally, <italic toggle="yes">HLA-F</italic> is associated with poor survival in some cancers, such as glioma and non-small-cell lung cancer [<xref rid="B109-ijms-27-00362" ref-type="bibr">109</xref>]. <italic toggle="yes">TRIAP1</italic> is involved in mitochondrial membrane homeostasis and cell protection from apoptosis, while <italic toggle="yes">TMBIM6</italic> is associated with resistance to stress-induced cell death [<xref rid="B110-ijms-27-00362" ref-type="bibr">110</xref>,<xref rid="B111-ijms-27-00362" ref-type="bibr">111</xref>]. Their suppression suggests enhanced apoptotic susceptibility when APB is used in conjunction with Dox. Additionally, <italic toggle="yes">ENTPD8</italic>, which has been linked to purinergic signalling and immune evasion in tumours, is also significantly downregulated, potentially improving immunogenicity [<xref rid="B112-ijms-27-00362" ref-type="bibr">112</xref>]. On the other hand, genes such as <italic toggle="yes">SERPINE1</italic>, <italic toggle="yes">USP17L4</italic>, and <italic toggle="yes">TSPAN3</italic> were significantly upregulated. <italic toggle="yes">SERPINE1</italic> (plasminogen activator inhibitor-1) is known to modulate extracellular matrix remodelling and may either promote or suppress tumour progression depending on context; however, in this combination, its induction may reflect a stress or reparative response to extensive damage (<xref rid="ijms-27-00362-f004" ref-type="fig">Figure 4</xref>A) [<xref rid="B113-ijms-27-00362" ref-type="bibr">113</xref>]. The upregulation of deubiquitinases like <italic toggle="yes">USP17L4</italic> and <italic toggle="yes">USP17L15</italic> could be compensatory but also point to altered proteostasis under APB+Dox treatment [<xref rid="B114-ijms-27-00362" ref-type="bibr">114</xref>].</p><p>The graphical summary of APB+Dox vs. APB and Dox monotreatment revealed a distinct suppression of tumour-promoting mechanisms in AGS gastric cancer cells, with a particular focus on <italic toggle="yes">CD44</italic>-driven signalling (<xref rid="ijms-27-00362-f004" ref-type="fig">Figure 4</xref>B). <italic toggle="yes">CD44</italic>, a well-established marker of cancer stem cells and a facilitator of tumour progression in gastric cancer, is central to this network [<xref rid="B115-ijms-27-00362" ref-type="bibr">115</xref>]. It influences key processes such as tumour cell interaction, migration, invasion, and fibrogenesis [<xref rid="B115-ijms-27-00362" ref-type="bibr">115</xref>]. Its downregulation, along with that of <italic toggle="yes">CD38</italic>, suggests a disruption in tumour&#8211;stromal interactions and extracellular matrix remodelling&#8212;hallmarks of aggressive gastric cancer phenotypes (<xref rid="ijms-27-00362-f004" ref-type="fig">Figure 4</xref>B) [<xref rid="B116-ijms-27-00362" ref-type="bibr">116</xref>]. The associated suppression of fibrogenesis-related genes like <italic toggle="yes">EPAS1</italic>, <italic toggle="yes">SMARCD3</italic>, and <italic toggle="yes">SYVN1</italic> supported the potential of combination therapy to interfere with tumour microenvironment remodelling, which is critical for tumour invasion and metastasis (<xref rid="ijms-27-00362-f004" ref-type="fig">Figure 4</xref>B) [<xref rid="B117-ijms-27-00362" ref-type="bibr">117</xref>]. Further, the network indicates transcriptional reprogramming as a major theme, with reduced activity in transcriptional regulators such as <italic toggle="yes">KLF4</italic>, and <italic toggle="yes">EPAS1</italic>, which have been implicated in gastric tumour growth and epithelial-to-mesenchymal transition (EMT) [<xref rid="B118-ijms-27-00362" ref-type="bibr">118</xref>,<xref rid="B119-ijms-27-00362" ref-type="bibr">119</xref>]. The suppression of genes like <italic toggle="yes">FOSL1</italic> and <italic toggle="yes">SYVN1</italic>, which support actin stress fibre formation and cellular motility, suggests impaired cytoskeletal dynamics and reduced metastatic capacity [<xref rid="B90-ijms-27-00362" ref-type="bibr">90</xref>,<xref rid="B120-ijms-27-00362" ref-type="bibr">120</xref>].</p><p>The canonical pathway analysis comparing APB+Dox to the monotreatments (APB and Dox individually) highlighted significant alterations in pathways related to cell cycle regulation, apoptosis, rRNA metabolic processes, and elements associated with invasion of tumour pathways (<xref rid="app1-ijms-27-00362" ref-type="app">Figure S2</xref>). There was marked upregulation of cell cycle checkpoints, DNA double-strand break response, and mitotic progression pathways, suggesting a strong activation of mechanisms that halted the cell cycle in response to genotoxic stress. This aligns with the mode of action of Dox, which induces DNA damage, and indicates that APB+Dox may enhance this effect to inhibit cancer cell proliferation [<xref rid="B121-ijms-27-00362" ref-type="bibr">121</xref>]. Pathways associated with apoptosis and cellular stress, including oxidative-stress-induced senescence and the senescence-associated secretory phenotype, were also upregulated, pointing to an increased likelihood of cancer cells undergoing programmed cell death or permanent arrest. Interestingly, rRNA-related processes such as RNA polymerase I transcription and regulation of rRNA expression were activated, possibly reflecting a cellular response to stress or compensatory mechanisms to maintain protein synthesis under damage conditions.</p><list list-type="simple"><list-item><p>Invasion of tumour pathways</p></list-item></list><p>The APB+Dox combination exerted potent anticancer effects in AGS gastric cancer cells by disrupting multiple pathways involved in tumour invasion, angiogenesis, and epithelial-to-mesenchymal transition (EMT). As illustrated by the network analysis, this treatment resulted in the coordinated downregulation of key genes associated with cell adhesion (e.g., <italic toggle="yes">CD44</italic> (&#8722;0.96), <italic toggle="yes">CD151</italic> (&#8722;1.03), <italic toggle="yes">ALCAM</italic> (&#8722;1.43), <italic toggle="yes">CLDN4</italic> (0.99), integrins (<italic toggle="yes">ITGA2</italic> (&#8722;0.60), <italic toggle="yes">ITGA6</italic> (&#8722;0.65), <italic toggle="yes">ITGB1</italic>(&#8722;0.59)), and extracellular matrix (ECM) remodelling proteins such as MMP14 (&#8722;1.07), CTSV (&#8722;1.18), and MDK (&#8722;2.24) (<xref rid="ijms-27-00362-f005" ref-type="fig">Figure 5</xref>). These changes suggest a marked impairment of tumour&#8722;stromal interactions and metastatic capacity. A particularly notable target, <italic toggle="yes">MDK</italic> (Midkine), a growth factor critical for angiogenesis and vascular remodelling, was significantly downregulated (log2FC = &#8722;2.24), indicating suppressed tumour-supporting vasculature. Similarly, <italic toggle="yes">TACSTD2</italic>, a gene linked to EMT and cancer progression, was strongly suppressed (log2FC = &#8722;2.49), likely contributing to reduced metastatic potential. Other downregulated factors such as <italic toggle="yes">ATP1B1</italic> (log2FC = &#8722;0.74), <italic toggle="yes">EPCAM</italic> (log2FC = &#8722;1.72), and <italic toggle="yes">CD44</italic> (log2FC = &#8722;0.96) further suggest disrupted cellular homeostasis, loss of cancer stemness, and inhibition of tumour recurrence (<xref rid="ijms-27-00362-f005" ref-type="fig">Figure 5</xref>).</p><p>Conversely, the upregulation of tumour suppressors like <italic toggle="yes">TP53</italic> (1.16) and <italic toggle="yes">RBM38</italic> (1.02), and stress regulators such as <italic toggle="yes">CLU</italic> (1.28), supports a shift towards apoptosis and reduced invasiveness. <italic toggle="yes">TGFBR1</italic> (&#8722;0.59), although typically involved in growth factor signalling, may, under this treatment context, exert anti-invasive effects. The network predominantly features predicted inhibitory interactions (blue arrows), reinforcing the hypothesis that APB+Dox disrupts invasion-related pathways through suppression of adhesion, ECM degradation, and cell signalling mechanisms. <italic toggle="yes">SNAI1</italic> (log2FC = 1.71), a key EMT transcription factor, and <italic toggle="yes">SERPINE1</italic> (log2FC = 3.14), a regulator of extracellular matrix remodelling and cell migration, were upregulated. This might suggest a partial or compensatory EMT response despite the broader anti-invasive effects of the treatment (<xref rid="ijms-27-00362-f005" ref-type="fig">Figure 5</xref>). Similarly, <italic toggle="yes">GDF15</italic> (log2FC = 0.91), typically linked to growth factor signalling, and <italic toggle="yes">CLDN4</italic> (log2FC = &#8722;0.99), involved in tight junction integrity, displayed expression patterns inconsistent with the predicted inhibition of tumour invasion (<xref rid="ijms-27-00362-f005" ref-type="fig">Figure 5</xref>). These signals may reflect a compensatory effect or stress adaptation mechanisms and highlight the complexity of interpreting network-level responses, where isolated proinvasive signals may persist within an overall suppressive theme.</p><list list-type="simple"><list-item><p>Apoptosis</p></list-item></list><p>The APB+Dox combination exerted a potent anticancer effect on AGS adenocarcinoma cells primarily through apoptosis modulation. Apoptosis is tightly regulated through both intrinsic (mitochondrial-mediated) and extrinsic (death-receptor-mediated) pathways [<xref rid="B122-ijms-27-00362" ref-type="bibr">122</xref>]. In AGS cells treated with the APB+Dox combination, the expression of proapoptotic and antiapoptotic factors was significantly altered, contributing to the observed therapeutic effects (<xref rid="app1-ijms-27-00362" ref-type="app">Figure S4</xref>).</p><list list-type="simple"><list-item><p>
<italic toggle="yes">Intrinsic Pathway of Apoptosis</italic>
</p></list-item></list><p>The intrinsic apoptotic pathway involves mitochondrial outer membrane permeabilization (MOMP), leading to cytochrome c release and caspase activation [<xref rid="B123-ijms-27-00362" ref-type="bibr">123</xref>]. <italic toggle="yes">BID</italic> (log2FC = &#8722;0.75), a BH3-only protein that activates BAX and BAK, showed a slight downregulation [<xref rid="B123-ijms-27-00362" ref-type="bibr">123</xref>]. Despite this, the proapoptotic <italic toggle="yes">BCL2L11</italic> (BIM, log2FC = 1.10) was upregulated, tipping the balance in favour of apoptosis by antagonizing antiapoptotic proteins like BCL-2 and BCL-XL [<xref rid="B124-ijms-27-00362" ref-type="bibr">124</xref>]. Concurrently, <italic toggle="yes">CASP9</italic> (log2FC = &#8722;0.69), essential for apoptosome formation, was modestly downregulated, potentially modulating the extent of apoptosis [<xref rid="B125-ijms-27-00362" ref-type="bibr">125</xref>]. Several genes influencing redox balance and mitochondrial health, such as <italic toggle="yes">ERO1B</italic> (log2FC = &#8722;2.76) and <italic toggle="yes">ENDOG</italic> (log2FC = &#8722;0.91), were downregulated. <italic toggle="yes">ERO1B</italic>&#8217;s decrease may amplify ER-stress-mediated apoptosis, while <italic toggle="yes">ENDOG</italic>&#8217;s reduction might partially offset DNA fragmentation effects [<xref rid="B126-ijms-27-00362" ref-type="bibr">126</xref>,<xref rid="B127-ijms-27-00362" ref-type="bibr">127</xref>]. Additionally, <italic toggle="yes">ERN1</italic> (log2FC = 1.65), associated with the unfolded protein response (UPR), was upregulated, indicating enhanced ER stress that can synergize with mitochondrial apoptosis [<xref rid="B128-ijms-27-00362" ref-type="bibr">128</xref>].</p><list list-type="simple"><list-item><p>
<italic toggle="yes">Extrinsic Pathway of Apoptosis</italic>
</p></list-item></list><p>The extrinsic pathway is impacted through the modulation of death receptor signalling [<xref rid="B123-ijms-27-00362" ref-type="bibr">123</xref>]. <italic toggle="yes">TNFRSF10B</italic> (TRAIL receptor 2, log2FC = &#8722;1.19) and <italic toggle="yes">TRADD</italic> (log2FC = &#8722;0.67) were downregulated upon APB+Dox treatment, which could dampen direct TRAIL-mediated apoptosis [<xref rid="B129-ijms-27-00362" ref-type="bibr">129</xref>,<xref rid="B130-ijms-27-00362" ref-type="bibr">130</xref>]. However, TRAIL expression and its downstream signalling may still induce apoptosis in susceptible cells [<xref rid="B129-ijms-27-00362" ref-type="bibr">129</xref>]. <italic toggle="yes">CASP10</italic> (log2FC = &#8722;0.68), a caspase involved in extrinsic pathway signalling, showed slight downregulation, but this effect may not fully abrogate extrinsic apoptosis.</p><list list-type="simple"><list-item><p>
<italic toggle="yes">Crosstalk Between Pathways</italic>
</p></list-item></list><p>The APB+Dox combination facilitated crosstalk between the intrinsic and extrinsic pathways. <italic toggle="yes">JUN</italic> (log2FC = 0.60), part of the AP-1 transcription complex, was upregulated, potentially driving proapoptotic gene expression [<xref rid="B131-ijms-27-00362" ref-type="bibr">131</xref>]. Similarly, <italic toggle="yes">TP53</italic> (log2FC = 1.16), the &#8220;guardian of the genome&#8221;, was upregulated, enhancing both intrinsic and extrinsic apoptosis by potentially inducing genes like <italic toggle="yes">BAX</italic>, <italic toggle="yes">PUMA</italic>, and <italic toggle="yes">NOXA</italic> [<xref rid="B132-ijms-27-00362" ref-type="bibr">132</xref>]. <italic toggle="yes">TP53</italic> upregulation was also observed in the Dox-only treatment (log2FC = 2.94), where it contributed to cell cycle arrest via activation of the CDK inhibitor p21 (CDKN1A), which inhibits CDK4/6 and halts progression through the G1/S checkpoint. In the APB+Dox group, <italic toggle="yes">TP53</italic> activation may also counteract the survival-promoting influence of antiapoptotic genes such as <italic toggle="yes">RAF1</italic> (log2FC = 0.89) [<xref rid="B133-ijms-27-00362" ref-type="bibr">133</xref>]. <italic toggle="yes">TP53</italic> acts as a central regulator of cellular fate, integrating multiple stress responses to maintain genomic integrity. As shown in <xref rid="app1-ijms-27-00362" ref-type="app">Figure S4</xref>, TP53 promotes apoptosis through activation of proapoptotic genes such as <italic toggle="yes">BAX</italic>, <italic toggle="yes">PMAIP1</italic> (PUMA), <italic toggle="yes">BBC3</italic>, and <italic toggle="yes">CASP6</italic>, while simultaneously inhibiting cell survival by repressing antiapoptotic factors including <italic toggle="yes">BCL2</italic>, <italic toggle="yes">BCL2L1</italic>, and <italic toggle="yes">BIRC5</italic> [<xref rid="B134-ijms-27-00362" ref-type="bibr">134</xref>,<xref rid="B135-ijms-27-00362" ref-type="bibr">135</xref>]. <italic toggle="yes">TP53</italic> also induces autophagy via DRAM1 and promotes senescence through <italic toggle="yes">SERPINE2</italic>, reinforcing its role in halting the proliferation of damaged cells [<xref rid="B136-ijms-27-00362" ref-type="bibr">136</xref>,<xref rid="B137-ijms-27-00362" ref-type="bibr">137</xref>]. Moreover, <italic toggle="yes">TP53</italic> enhances mitochondrial respiration by activating <italic toggle="yes">SCO2</italic> (log2FC = 0.74), which supports oxidative phosphorylation, while concurrently suppressing glycolysis through upregulation of <italic toggle="yes">TIGAR</italic>, thereby shifting metabolism away from anaerobic energy production [<xref rid="B138-ijms-27-00362" ref-type="bibr">138</xref>,<xref rid="B139-ijms-27-00362" ref-type="bibr">139</xref>].</p><list list-type="simple"><list-item><p>rRNA metabolic process</p></list-item></list><list list-type="simple"><list-item><p>
<italic toggle="yes">rRNA Biogenesis and Ribosomal Genes</italic>
</p></list-item></list><p>Ribosome biogenesis is a hallmark of rapidly dividing cancer cells. Key genes involved in rRNA synthesis and ribosome function, including <italic toggle="yes">RPL14</italic> (log2FC = 0.59), <italic toggle="yes">UBA52</italic> (log2FC = 0.60), and <italic toggle="yes">RRN3</italic> (log2FC = 0.76), were upregulated in response to APB+Dox treatment [<xref rid="B140-ijms-27-00362" ref-type="bibr">140</xref>,<xref rid="B141-ijms-27-00362" ref-type="bibr">141</xref>,<xref rid="B142-ijms-27-00362" ref-type="bibr">142</xref>]. While these proteins are generally associated with ribosome assembly, their increased expression in this context may reflect a compensatory or stress-adaptive response rather than enhanced global protein synthesis. <italic toggle="yes">UBA52</italic> has been reported to simultaneously deliver both <italic toggle="yes">RPL40</italic> and ubiquitin to the ribosome [<xref rid="B141-ijms-27-00362" ref-type="bibr">141</xref>]. These genes play a critical role in driving ribosome assembly and protein synthesis, processes essential for tumour progression. Elevated expression of <italic toggle="yes">RPL14</italic> and <italic toggle="yes">UBA52</italic> has been linked to increased protein synthesis, metabolic adaptation, and enhanced resistance to cellular stress. Notably, higher levels of <italic toggle="yes">RPL14</italic> have also been shown to suppress cell migration and invasion in nasopharyngeal carcinoma [<xref rid="B140-ijms-27-00362" ref-type="bibr">140</xref>]. Conversely, <italic toggle="yes">RIOK2</italic> (log2FC = &#8722;0.95), a kinase promoting ribosome assembly, was downregulated, potentially disrupting ribosome biogenesis [<xref rid="B65-ijms-27-00362" ref-type="bibr">65</xref>]. This downregulation may inhibit tumour growth by reducing ribosomal output and impairing the protein synthesis machinery that supports cancer cell proliferation [<xref rid="B65-ijms-27-00362" ref-type="bibr">65</xref>].</p><list list-type="simple"><list-item><p>
<italic toggle="yes">RNA Processing and Splicing</italic>
</p></list-item></list><p>The APB+Dox combination influences genes involved in RNA processing and splicing, key processes in post-transcriptional gene regulation. Genes such as <italic toggle="yes">SMN2</italic> (log2FC = 0.73) and <italic toggle="yes">ISY1</italic> (log2FC = 0.69), involved in RNA splicing, were upregulated, suggesting an adaptive response to therapy [<xref rid="B143-ijms-27-00362" ref-type="bibr">143</xref>,<xref rid="B144-ijms-27-00362" ref-type="bibr">144</xref>]. Increased RNA splicing activity could represent an effort by cancer cells to maintain proper gene expression under therapeutic stress. In contrast, <italic toggle="yes">DCAF13</italic> (log2FC = &#8722;1.77), which regulates ubiquitination and degradation of proteins, was significantly downregulated [<xref rid="B145-ijms-27-00362" ref-type="bibr">145</xref>]. <italic toggle="yes">DCAF13</italic>, a substrate receptor in the CUL4-DDB1 E3 ligase, is known for promoting cancer cell migration, invasion, and epithelial&#8211;mesenchymal transition [<xref rid="B146-ijms-27-00362" ref-type="bibr">146</xref>]. Interestingly, while Dox treatment has been reported to upregulate <italic toggle="yes">DCAF13</italic>, potentially enhancing metastatic risk, SCFAs may counteract this effect by downregulating <italic toggle="yes">DCAF13</italic> (&#8722;1.77 for APB+Dox treatment), offering a therapeutic advantage in reducing metastasis during chemotherapy [<xref rid="B146-ijms-27-00362" ref-type="bibr">146</xref>]. The APB+Dox combination exerted its anticancer effects by targeting vulnerabilities in the rRNA metabolic process. While some ribosomal and RNA processing genes are upregulated, potentially as a compensatory response, the downregulation of critical genes like <italic toggle="yes">RIOK2</italic> and <italic toggle="yes">DCAF13</italic> potentially disrupted ribosome biogenesis and protein degradation pathways. This dual modulation leads to metabolic and nucleolar stress, impairing the cancer cell&#8217;s ability to sustain rapid growth and survival.</p><list list-type="simple"><list-item><p>Cell Cycle</p></list-item></list><p>The APB+Dox combination substantially impacted the cell cycle in AGS gastric cancer cells, disrupting essential processes related to mitosis, chromatin organization, and DNA repair. These effects collectively impair normal cell division, contributing to the anticancer efficacy of the treatment. In the current study, APB+Dox treatment led to marked upregulation of <italic toggle="yes">TP53</italic> (log2FC = 1.16) and several key checkpoint regulators, including <italic toggle="yes">CHEK2</italic> (log2FC = 0.86), <italic toggle="yes">CDC20</italic> (log2FC = 1.24), and <italic toggle="yes">CDCA8</italic> (log2FC = 0.74) [<xref rid="B134-ijms-27-00362" ref-type="bibr">134</xref>]. It is noteworthy that the Dox treatment resulted in upregulation of <italic toggle="yes">TP53</italic> (log2FC = 2.94). Interestingly, this was accompanied by the downregulation of negative mitotic regulators such as <italic toggle="yes">PKMYT1</italic> (log2FC = &#8722;0.65) and <italic toggle="yes">UBE2N</italic> (log2FC = &#8722;1.02), suggesting a coordinated shift toward checkpoint activation rather than evasion. Notably, overexpression of <italic toggle="yes">PKMYT1</italic> and <italic toggle="yes">UBE2N</italic> has been associated with poor prognosis in breast and prostate cancers, respectively, supporting their role in tumour progression [<xref rid="B147-ijms-27-00362" ref-type="bibr">147</xref>,<xref rid="B148-ijms-27-00362" ref-type="bibr">148</xref>]. Additionally, the suppression of <italic toggle="yes">UBE2N</italic>, <italic toggle="yes">UBE2C</italic>, and <italic toggle="yes">PSMB10</italic> (log2FC = &#8722;1.02 to &#8722;0.72)&#8212;key components of the ubiquitin&#8211;proteasome system&#8212;indicates inhibition of proteasomal degradation, which may stabilize proapoptotic proteins and enhance cell death [<xref rid="B147-ijms-27-00362" ref-type="bibr">147</xref>,<xref rid="B149-ijms-27-00362" ref-type="bibr">149</xref>,<xref rid="B150-ijms-27-00362" ref-type="bibr">150</xref>]. Other mitotic regulators such as <italic toggle="yes">SGO2</italic> and <italic toggle="yes">PKMYT1</italic>, which are crucial for chromosome cohesion and <italic toggle="yes">CDK1</italic> inhibition, were also downregulated (log2FC = &#8722;0.89 and &#8722;0.65, respectively), suggesting further interference with proper mitotic progression [<xref rid="B151-ijms-27-00362" ref-type="bibr">151</xref>]. A notable target is <italic toggle="yes">KLHL21</italic> (Kelch-like protein 21), which was significantly upregulated (log2FC = 2.06) [<xref rid="B152-ijms-27-00362" ref-type="bibr">152</xref>]. <italic toggle="yes">KLHL21</italic> is essential for mitotic progression and cytokinesis, ensuring accurate chromosome segregation during cell division. Its upregulation under APB+Dox treatment may counteract <italic toggle="yes">KLHL21</italic> loss observed in gastric cancer, which is known to enhance STAT3 activation and promote tumour progression [<xref rid="B153-ijms-27-00362" ref-type="bibr">153</xref>]. Restoring <italic toggle="yes">KLHL21</italic> expression could improve chemotherapy response and inhibit the transition from metaplasia to dysplasia, offering a novel therapeutic strategy for gastric cancer management [<xref rid="B153-ijms-27-00362" ref-type="bibr">153</xref>].</p><p>Furthermore, histone cluster genes, including <italic toggle="yes">H2BC9</italic>, showed significant upregulation (log2FC = 2.51), indicating changes in nucleosome assembly and chromatin structure [<xref rid="B154-ijms-27-00362" ref-type="bibr">154</xref>]. These histones play critical roles in DNA replication, repair, and epigenetic regulation [<xref rid="B155-ijms-27-00362" ref-type="bibr">155</xref>]. Their altered expression suggests chromatin remodelling in response to APB+Dox, which may contribute to replication stress, cell cycle arrest, or apoptosis during the S phase. In contrast, <italic toggle="yes">SLX9</italic>, an <italic toggle="yes">RNA</italic> processing factor involved in ribosome biogenesis, was strongly downregulated (log2FC = &#8722;2.51) [<xref rid="B156-ijms-27-00362" ref-type="bibr">156</xref>,<xref rid="B157-ijms-27-00362" ref-type="bibr">157</xref>]. As ribosome synthesis is tightly linked to cell growth and the G1/S transition, <italic toggle="yes">SLX9</italic> suppression likely impaired protein synthesis, leading to growth arrest and enhanced cytotoxicity [<xref rid="B156-ijms-27-00362" ref-type="bibr">156</xref>,<xref rid="B157-ijms-27-00362" ref-type="bibr">157</xref>]. Finally, several genes involved in DNA repair and genome stability, including <italic toggle="yes">WRN</italic> (log2FC = 1.84), <italic toggle="yes">RRM2</italic> (log2FC = 1.00), and <italic toggle="yes">XRCC3</italic> (log2FC = 0.72), were upregulated, reflecting a cellular attempt to mitigate DNA damage induced by treatment [<xref rid="B158-ijms-27-00362" ref-type="bibr">158</xref>,<xref rid="B159-ijms-27-00362" ref-type="bibr">159</xref>,<xref rid="B160-ijms-27-00362" ref-type="bibr">160</xref>]. However, despite these adaptive responses, the extent of DNA damage and stress caused by APB+Dox may exceed the repair capacity, tipping the balance toward apoptosis and tumour regression.</p></sec></sec><sec id="sec2dot4-ijms-27-00362"><title>2.4. Flow Cytometric Analyses of Apoptotic Profiles of Mono and Combination Therapies</title><p>Recognized as a fundamental barrier to cancer progression, apoptosis, a form of programmed cell death, eliminates potentially malignant cells from the body, making it a central target in the development of many modern anticancer therapies [<xref rid="B123-ijms-27-00362" ref-type="bibr">123</xref>]. In this study, flow cytometry was used to distinguish between apoptotic and necrotic cell populations through the application of Annexin V and 7-AAD. Annexin V specifically detects phosphatidylserine, a phospholipid that becomes exposed on the outer leaflet of the plasma membrane during early apoptosis. In contrast, 7-AAD binds strongly to guanine&#8211;cytosine-rich regions of double-stranded DNA, allowing for the identification of necrotic cells. The results are classified into four groups: live cells, early-stage apoptotic cells, late-stage apoptotic cells, and necrotic cells. The effects of the monotreatments APB and Dox, along with the combination APB+Dox, were investigated using flow cytometric analysis, compared to the negative control (<xref rid="ijms-27-00362-f006" ref-type="fig">Figure 6</xref>).</p><p>APB (3000 &#956;g/mL) treatment produced 71.91% late apoptotic cells and 11.81% early apoptotic cells (<italic toggle="yes">p</italic> &lt; 0.0001), with low necrosis (3.32%) and 12.96% live cells (<italic toggle="yes">p</italic> &lt; 0.01). Dox (0.54 &#956;g/mL) treatment resulted in 57.40% late apoptotic cells, 3.95% early apoptotic cells (<italic toggle="yes">p</italic> &lt; 0.0001), and a higher necrotic fraction (38.49%), with only 0.16% live cells. The APB+Dox combination (3000 &#956;g/mL + 0.27 &#956;g/mL) yielded 64.56% late apoptotic cells and 30.27% early apoptotic cells (<italic toggle="yes">p</italic> &lt; 0.0001), with 4.64% necrotic cells and 0.53% live cells. The necrotic proportion in the combination group was notably lower than in the Dox-only group (38.49%) (<xref rid="ijms-27-00362-f006" ref-type="fig">Figure 6</xref>).</p></sec><sec id="sec2dot5-ijms-27-00362"><title>2.5. ROS Production in the AGS Cells After Treatment with Different Concentrations of APB, Dox, and APB+Dox</title><p>ROS play a dual role in cancer biology, where their excessive accumulation, commonly referred to as oxidative stress, can contribute to both tumour initiation and progression [<xref rid="B161-ijms-27-00362" ref-type="bibr">161</xref>]. Interestingly, manipulating ROS levels within cancer cells, either by promoting their accumulation to toxic levels or by disrupting the redox balance, has emerged as a promising approach in the development of anticancer therapies [<xref rid="B161-ijms-27-00362" ref-type="bibr">161</xref>]. TBHP, used as a positive control for ROS induction, produced a significant increase in ROS levels (11.94-fold) compared to the untreated control (<xref rid="ijms-27-00362-f007" ref-type="fig">Figure 7</xref>). At 3000 &#956;g/mL, APB alone induced a 6.14-fold increase in ROS relative to control. The combination of APB+Dox at the same concentration (3000 &#956;g/mL + 0.27 &#956;g/mL) resulted in a similar ROS increase (6.17-fold), indicating that Dox did not markedly alter APB&#8217;s pro-oxidative effect at this dose. APB combined with Dox at lower concentrations produced ROS levels of 2.99-fold. In contrast, Dox alone at comparable concentrations yielded lower ROS increases (0.99&#8211;1.04-fold).</p></sec></sec><sec id="sec3-ijms-27-00362"><title>3. Materials and Methods</title><sec id="sec3dot1-ijms-27-00362"><title>3.1. Chemicals and Drug Preparation</title><p>All solvents used in this study were of analytical grade and procured from Sigma Aldrich (Castle Hill, NSW, Australia). Magnesium acetate (A), sodium propionate (P), sodium butyrate (B), and Dox were also obtained from Sigma Aldrich (Castle Hill, NSW, Australia). Additionally, all reagents were prepared following the standard procedures and protocols specified in the assay kits.</p></sec><sec id="sec3dot2-ijms-27-00362"><title>3.2. Cell Culture</title><p>The AGS gastric adenocarcinoma (CRL-1739, ATCC) and HS738.St/Int stomach intestinal (CRL-7869, ATCC) cell lines were sourced from the American Type Culture Collection (ATCC, Manassas, VA, USA). AGS cells were maintained in ATCC-formulated F-12K medium (Kaighn&#8217;s Modification of Ham&#8217;s F-12), supplemented with 2 mM L-glutamine, 1500 mg/L sodium bicarbonate, 10% foetal bovine serum (Bio-Strategy PTY, Campbellfield, VIC, Australia), and 1% penicillin&#8211;streptomycin (Sigma-Aldrich, Castle Hill, NSW, Australia). HS738.St/Int cells were cultured in ATCC-formulated DMEM (Dulbecco&#8217;s Modified Eagle Medium, ATCC, VA, USA). containing 4.5 g/L glucose, L-glutamine, sodium pyruvate, 10% foetal bovine serum, and 1% penicillin&#8211;streptomycin. Both cell lines were incubated at 37 &#176;C in a humidified atmosphere of 5% CO<sub>2</sub>, with maintenance performed every 48&#8211;72 h to sustain confluent monolayers.</p></sec><sec id="sec3dot3-ijms-27-00362"><title>3.3. Cell Viability Assays</title><p>The cell viability of AGS cells after exposure to varying concentrations of SCFAs combinations (APB), Dox, and the combined treatment (APB+Dox) was evaluated using the Alamar Blue assay, following previously established protocols [<xref rid="B162-ijms-27-00362" ref-type="bibr">162</xref>]. Briefly, 100 &#181;L of AGS cells were seeded at a density of 10<sup>5</sup> cells/mL into 96-well plates and allowed to adhere for 24 h. The cells were then treated with the test samples and incubated for 72 h. Dox at a concentration of 1 &#181;M was also used as a positive control, while 0.1% DMSO served as a negative control across all plates. After the incubation period, the culture medium was removed, and 100 &#181;L of a freshly prepared 0.1 mg/mL Alamar Blue solution was added to each well. The Alamar Blue solution was made by diluting a 1 mg/mL resazurin stock in PBS at a 1:10 ratio with serum-free media. Fluorescence measurements were obtained using a microplate spectrophotometer (BMG CLARIOstar, Mornington, VIC, Australia) with excitation and emission wavelengths of 555 nm and 595 nm, respectively. Each sample was tested in triplicate, and cell viability in the negative control group was normalized to 100%.</p></sec><sec id="sec3dot4-ijms-27-00362"><title>3.4. Synergy</title><p>Dox was combined with the SCFAs mixture APB at a 1:1 ratio to perform combination index (CI) analyses. The potential interactions between Dox and APB were evaluated using the CI model, with calculations conducted via CompuSyn version 2.0 software (Biosoft, El Cajon, CA, USA). The CI calculations were based on the median-effect equation, derived from the mass action law [<xref rid="B163-ijms-27-00362" ref-type="bibr">163</xref>]. In this study, the APB+Dox combination was analysed using a six-point dose&#8211;response curve within the CI framework.</p></sec><sec id="sec3dot5-ijms-27-00362"><title>3.5. Liquid Chromatography&#8211;Mass Spectrometry, Label-Free Quantification Bottom-Up Proteomics</title><p>All reagents were purchased from Thermo Fisher Scientific (Waltham, MA, USA) unless stated otherwise. Proteomics studies were conducted following a recently established protocol. AGS gastric adenocarcinoma cells were cultured and treated in T75 flasks with APB, Dox, or their combination, APB+Dox, for 24 h. Post-treatment, cells were harvested, washed, and lysed in a sodium-deoxycholate-based buffer. Protein extraction involved sonication, centrifugation, and acetone precipitation. Protein pellets were reduced, alkylated, quantified, and digested overnight with trypsin. Peptides were desalted, dried, and resuspended in loading buffer before LC&#8211;MS analysis. Peptide separation was performed using nano-liquid chromatography (Ultimate 3000 HPLC, (Thermo Fisher Scientific, Waltham, MA, USA with a 75 &#956;m &#215; 45 cm C18 column and a gradient elution protocol. Mass spectrometry was conducted on a Q Exactive HF-X Orbitrap (Thermo Fisher Scientific, Waltham, MA, USA), in data-independent acquisition (DIA) mode, capturing full MS scans and sequential fragmentation across <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> windows. Raw data were processed using Spectronaut (v19) with the directDIA+ workflow against the 2023 UniProt human database. Parameters included trypsin digestion, dynamic modifications (oxidation, N-terminal acetylation), and fixed carbamidomethylation. False discovery rates for peptide-spectrum matches, peptides, and protein groups were set at 1%. Quantification was based on MS1 peak area, and differential abundance was assessed using unpaired t-tests. Data were deposited in PRIDE (PXD061824).</p></sec><sec id="sec3dot6-ijms-27-00362"><title>3.6. Flow Cytometry</title><p>The effects of APB, Dox, and APB+Dox on the apoptosis profiles of AGS adenocarcinoma cells were evaluated using an annexin V and 7-AAD-based apoptosis detection kit (#ab214663, Abcam, Melbourne, VIC, Australia) following established protocols [<xref rid="B33-ijms-27-00362" ref-type="bibr">33</xref>,<xref rid="B163-ijms-27-00362" ref-type="bibr">163</xref>]. Briefly, AGS gastric cancer cells (1 &#215; 10<sup>6</sup> cells/10 mL) were seeded in T75 flasks and incubated for 24 h at 37 &#176;C with 5% CO<sub>2</sub>. Cells were then treated with APB (3000 &#181;g/mL), doxorubicin (Dox, 0.54 &#181;g/mL), their combination (APB+Dox), and just growth media (untreated control). After 24 h of treatment, apoptosis was assessed using the Annexin V-CF Blue/7-AAD staining kit (Abcam, #ab214663), following the manufacturer&#8217;s instructions. Cells were harvested, stained, and analysed via flow cytometry (Novocyte 3000, ACEA Biosciences, San Diego, CA, USA). Data were initially gated to exclude debris and doublets based on forward and side scatter properties. Cell populations were then classified according to Annexin V and 7-AAD fluorescence as follows: live cells (Annexin V<sup>&#8722;</sup>/7-AAD<sup>&#8722;</sup>), early apoptotic cells (Annexin V<sup>+</sup>/7-AAD<sup>&#8722;</sup>), late apoptotic cells (Annexin V<sup>+</sup>/7-AAD<sup>+</sup>), and necrotic cells (Annexin V<sup>&#8722;</sup>/7-AAD<sup>+</sup>). Data from three independent biological replicates per group were analysed using NovoExpress software (v1.5.0).</p></sec><sec id="sec3dot7-ijms-27-00362"><title>3.7. ROS Production Analysis</title><p>The impact of Dox, APB, and their combination (APB+Dox) on oxidative stress in AGS gastric adenocarcinoma cells was assessed using the H2DCFDA (2&#8242;,7&#8242;-dichlorofluorescein diacetate) Cellular Reactive Oxygen Species (ROS) Detection Assay Kit (#ab113851; Abcam, Melbourne, VIC, Australia) following a recently established protocol [<xref rid="B164-ijms-27-00362" ref-type="bibr">164</xref>]. Briefly, AGS cells were seeded at a density of 2.5 &#215; 10<sup>5</sup> cells/mL in a 96-well plate and allowed to adhere overnight. To measure ROS levels, the cells were treated with 20 &#956;M H2DCFDA for 45 min. After removing the dye solution, the cells were washed with 1x buffer and then exposed to 750, 1500, and 3000 &#181;g/mL of SCFAs combination APB; 0.54 &#181;g/mL (1 &#956;M) of Dox, APB+Dox (1:1), and 250 &#956;M of tert-butyl hydroperoxide (TBHP; positive control). The cells were incubated at 37 &#176;C for 4 h and fluorescence was measured using a microplate spectrophotometer (BMG CLARIOstar, Mornington, VIC, Australia) at an excitation/emission wavelength of 485/535 nm. The fold change in ROS production was calculated relative to the untreated control, where cells were treated with buffer according to the manufacturer&#8217;s instructions.</p></sec><sec id="sec3dot8-ijms-27-00362"><title>3.8. Statistical Analysis</title><p>Data collection and analysis were carried out using Microsoft Excel (MS Office 2021) for data management and GraphPad Prism (version 9.0, San Diego, CA, USA) for statistical analysis and visualization. All experiments were conducted in triplicate, with results expressed as the mean &#177; standard deviation (SD). Statistical significance between mean values was evaluated using a two-way ANOVA, with a significance threshold set at <italic toggle="yes">p</italic> &lt; 0.05. The IC50 values, representing the concentration of a drug required to inhibit cell growth by 50%, were calculated using GraphPad Prism 9.0. Non-linear regression analysis was also performed using the same software for IC50 determination. The designation n = 3 corresponds to the number of independent biological replicates included in the analyses.</p></sec></sec><sec sec-type="conclusions" id="sec4-ijms-27-00362"><title>4. Conclusions</title><p>The current study shows that dietary SCFAs, specifically acetate, propionate, and butyrate (APB), can work synergistically with Dox to enhance anticancer activity in AGS gastric cancer cells. Our findings demonstrate that the APB+Dox combination significantly enhances antiproliferative effects compared to either agent alone, as evidenced by a substantial reduction in IC<sub>50</sub> values and a strong synergistic interaction confirmed by combination index analysis. Mechanistically, this synergy appears to be mediated through multiple pathways. The APB+Dox combination exerted a synergistic anticancer effect on AGS gastric cancer cells by modulating key pathways involved in cell survival, apoptosis, cell cycle regulation, immune evasion, and tumour microenvironment remodelling.</p><p>The proteomic analyses revealed that the combination treatment significantly downregulated tumour-promoting genes such as <italic toggle="yes">HLA-F</italic>, <italic toggle="yes">TRIAP1</italic>, <italic toggle="yes">TMBIM6</italic>, and <italic toggle="yes">ENTPD8</italic>, suggesting reduced mitochondrial integrity and immune escape, thereby enhancing apoptotic susceptibility. Simultaneously, upregulation of <italic toggle="yes">SERPINE1</italic>, <italic toggle="yes">USP17L4</italic>, and components of the TP53 network reflected increased genotoxic stress responses and proteostasis alterations. Network and pathway enrichment analyses highlighted suppression of CD44-centred signalling, epithelial&#8211;mesenchymal transition (EMT), and fibrogenesis-related genes, indicating impaired tumour plasticity and reduced metastatic potential. Canonical pathway analysis revealed pronounced activation of DNA damage checkpoints, oxidative stress responses, and cell cycle arrest, supporting the enhanced cytostatic and proapoptotic effects of APB+Dox. Apoptosis induction occurred via both intrinsic and extrinsic pathways, with increased expression of proapoptotic regulators (<italic toggle="yes">TP53</italic>, <italic toggle="yes">BCL2L11</italic>) and downregulation of survival-promoting genes (<italic toggle="yes">MDK</italic>, <italic toggle="yes">TNFRSF10B</italic>, <italic toggle="yes">DCAF13</italic>), tipping the balance toward programmed cell death. The combination also disrupted ribosome biogenesis and RNA processing, impairing protein synthesis and contributing to metabolic stress. Finally, modulation of haemostasis-related factors such as <italic toggle="yes">MDK</italic> and <italic toggle="yes">TACSTD2</italic> further inhibited angiogenesis and tumour-associated signalling. Altogether, this study demonstrates that APB enhances Dox efficacy by disrupting AGS cell homeostasis at multiple levels, supporting its potential role as a promising adjuvant strategy in gastric cancer therapy.</p><p>While these findings provide valuable mechanistic evidence for the synergistic anticancer effects of APB and Dox in gastric cancer cells, further discussion is warranted regarding their potential translation into real-world clinical settings. In particular, considerations such as physiological relevance of SCFA concentrations, feasibility of achieving therapeutic levels through diet or supplementation, interactions with standard chemotherapy regimens, patient heterogeneity, and safety profiles in vivo should be addressed. Importantly, the clinical implementation of SCFA-based adjuvant strategies also presents both challenges and opportunities. SCFAs are endogenously produced metabolites with favourable safety profiles, but their delivery alongside chemotherapy will require careful consideration of formulation, route of administration, and stability. Potential approaches may include dietary modulation, prebiotic supplementation to enhance endogenous SCFA production, or controlled-release formulations designed to achieve sustained and localised exposure. Addressing these practical aspects through preclinical animal studies and well-designed clinical trials will be essential to determine whether SCFA-based adjuvant strategies can meaningfully enhance therapeutic outcomes and reduce chemotherapy-associated toxicity in patients with gastric cancer.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge and pay respect to the Traditional Owners&#8212;the Darug People (Darug Nation: Western Sydney University Westmead and Penrith Campuses), the Bidigal People (Dharawal Nation: Western Sydney University Campbelltown Campus), and the Gadigal People (Eora Nation: The University of Sydney)&#8212;of the land on which we research, teach, and collaborate. The authors would also like to acknowledge the University of Sydney Mass Spectrometry Facility for providing access to its instrumentation and assistance with the MS analyses. The authors also acknowledge the Freedman Foundation Metabolomics Facility at the Innovation Centre, Victor Chang Cardiac Research Institute, which is supported by funding from the NSW Government.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-ijms-27-00362"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/ijms27010362/s1">https://www.mdpi.com/article/10.3390/ijms27010362/s1</uri>.</p><supplementary-material id="ijms-27-00362-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ijms-27-00362-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualisation, R.A.E. and D.J.B.; methodology, R.A.E.; investigation, R.A.E.; formal analysis, R.A.E., M.F. and M.A.A.; data curation, R.A.E.; writing&#8212;original draft preparation, R.A.E. and M.F.; writing&#8212;review and editing, R.A.E., M.F., M.A.A., D.C., C.-G.L. and D.J.B.; supervision, D.J.B., D.C. and C.-G.L. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The raw and processed data have been deposited to the ProteomeXchange.Consortium via the PRoteomics IDEntifications (PRIDE) repository with the dataset identifier PXD061824.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-27-00362"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA A Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="B2-ijms-27-00362"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Torre</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA A Cancer J. Clin.</source><year>2018</year><volume>68</volume><fpage>394</fpage><lpage>424</lpage><comment>Erratum in <italic toggle="yes">CA Cancer J Clin.</italic><bold>2020</bold>, <italic toggle="yes">70</italic>, 313</comment><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation></ref><ref id="B3-ijms-27-00362"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Japanese Gastric Cancer Association</collab></person-group><article-title>Japanese gastric cancer treatment guidelines 2018</article-title><source>Gastric Cancer</source><year>2021</year><volume>24</volume><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1007/s10120-020-01042-y</pub-id><pub-id pub-id-type="pmid">32060757</pub-id><pub-id pub-id-type="pmcid">PMC7790804</pub-id></element-citation></ref><ref id="B4-ijms-27-00362"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bang</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Van Cutsem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Feyereislova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sawaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lordick</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ohtsu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Omuro</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>T.</given-names></name></person-group><article-title>Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><fpage>687</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61121-X</pub-id><pub-id pub-id-type="pmid">20728210</pub-id></element-citation></ref><ref id="B5-ijms-27-00362"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name></person-group><article-title>Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signalling pathway in gastric cancer</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2017</year><volume>36</volume><fpage>19</fpage><pub-id pub-id-type="doi">10.1186/s13046-016-0487-8</pub-id><pub-id pub-id-type="pmid">28126034</pub-id><pub-id pub-id-type="pmcid">PMC5270306</pub-id></element-citation></ref><ref id="B6-ijms-27-00362"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canani</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Di Costanzo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leone</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pedata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Calignano</surname><given-names>A.</given-names></name></person-group><article-title>Potential beneficial effects of butyrate in intestinal and extraintestinal diseases</article-title><source>World J. Gastroenterol.</source><year>2011</year><volume>17</volume><fpage>1519</fpage><pub-id pub-id-type="doi">10.3748/wjg.v17.i12.1519</pub-id><pub-id pub-id-type="pmid">21472114</pub-id><pub-id pub-id-type="pmcid">PMC3070119</pub-id></element-citation></ref><ref id="B7-ijms-27-00362"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tacar</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sriamornsak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dass</surname><given-names>C.R.</given-names></name></person-group><article-title>Doxorubicin: An update on anticancer molecular action, toxicity and novel drug delivery systems</article-title><source>J. Pharm. Pharmacol.</source><year>2013</year><volume>65</volume><fpage>157</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.2012.01567.x</pub-id><pub-id pub-id-type="pmid">23278683</pub-id></element-citation></ref><ref id="B8-ijms-27-00362"><label>8.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Yonemura</surname><given-names>Y.</given-names></name></person-group><article-title>Mechanisms of drug resistance in gastric cancer</article-title><source>Contemporary Approaches Toward Cure of Gastric Cancer</source><publisher-name>Maeda Shoten Co. Ltd.</publisher-name><publisher-loc>Kanazawa, Japan</publisher-loc><year>1996</year><fpage>87</fpage><lpage>91</lpage></element-citation></ref><ref id="B9-ijms-27-00362"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alkuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Al-Hussaniy</surname><given-names>H.A.</given-names></name></person-group><article-title>Doxorubicin-induced cardiotoxicity: Molecular mechanism and protection by conventional drugs and natural products</article-title><source>Int. J. Clin. Oncol. Cancer Res.</source><year>2017</year><volume>2</volume><fpage>31</fpage><lpage>44</lpage></element-citation></ref><ref id="B10-ijms-27-00362"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gianni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Lipshultz</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Minotti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sarvazyan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sawyer</surname><given-names>D.B.</given-names></name></person-group><article-title>Anthracycline cardiotoxicity: From bench to bedside</article-title><source>J. Clin. Oncol.</source><year>2008</year><volume>26</volume><fpage>3777</fpage><lpage>3784</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.9401</pub-id><pub-id pub-id-type="pmid">18669466</pub-id><pub-id pub-id-type="pmcid">PMC3018290</pub-id></element-citation></ref><ref id="B11-ijms-27-00362"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Drug resistance and combating drug resistance in cancer</article-title><source>Cancer Drug Resist.</source><year>2019</year><volume>2</volume><fpage>141</fpage><pub-id pub-id-type="doi">10.20517/cdr.2019.10</pub-id><pub-id pub-id-type="pmid">34322663</pub-id><pub-id pub-id-type="pmcid">PMC8315569</pub-id></element-citation></ref><ref id="B12-ijms-27-00362"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Severino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tohumcu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tamai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dargenio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Porcari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rondinella</surname><given-names>D.</given-names></name><name name-style="western"><surname>Venturini</surname><given-names>I.</given-names></name><name name-style="western"><surname>Maida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gasbarrini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cammarota</surname><given-names>G.</given-names></name></person-group><article-title>The microbiome-driven impact of western diet in the development of noncommunicable chronic disorders</article-title><source>Best Pract. Res. Clin. Gastroenterol.</source><year>2024</year><volume>72</volume><fpage>101923</fpage><pub-id pub-id-type="doi">10.1016/j.bpg.2024.101923</pub-id><pub-id pub-id-type="pmid">39645277</pub-id></element-citation></ref><ref id="B13-ijms-27-00362"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Ucmak</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abrouk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farahnik</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>T.H.</given-names></name></person-group><article-title>Influence of diet on the gut microbiome and implications for human health</article-title><source>J. Transl. Med.</source><year>2017</year><volume>15</volume><fpage>73</fpage><pub-id pub-id-type="doi">10.1186/s12967-017-1175-y</pub-id><pub-id pub-id-type="pmid">28388917</pub-id><pub-id pub-id-type="pmcid">PMC5385025</pub-id></element-citation></ref><ref id="B14-ijms-27-00362"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deleu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Machiels</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Verbeke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vermeire</surname><given-names>S.</given-names></name></person-group><article-title>Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?</article-title><source>EBioMedicine</source><year>2021</year><volume>66</volume><fpage>103293</fpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2021.103293</pub-id><pub-id pub-id-type="pmid">33813134</pub-id><pub-id pub-id-type="pmcid">PMC8047503</pub-id></element-citation></ref><ref id="B15-ijms-27-00362"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>O.</given-names></name></person-group><article-title>Gut microbiota in human metabolic health and disease</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>19</volume><fpage>55</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1038/s41579-020-0433-9</pub-id><pub-id pub-id-type="pmid">32887946</pub-id></element-citation></ref><ref id="B16-ijms-27-00362"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Bernardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frozza</surname><given-names>R.L.</given-names></name></person-group><article-title>The role of short-chain fatty acids from gut microbiota in gut-brain communication</article-title><source>Front. Endocrinol.</source><year>2020</year><volume>11</volume><elocation-id>25</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2020.00025</pub-id><pub-id pub-id-type="pmcid">PMC7005631</pub-id><pub-id pub-id-type="pmid">32082260</pub-id></element-citation></ref><ref id="B17-ijms-27-00362"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaye</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bhuyan</surname><given-names>D.J.</given-names></name></person-group><article-title>The role of key gut microbial metabolites in the development and treatment of cancer</article-title><source>Gut Microbes</source><year>2022</year><volume>14</volume><fpage>2038865</fpage><pub-id pub-id-type="doi">10.1080/19490976.2022.2038865</pub-id><pub-id pub-id-type="pmid">35220885</pub-id><pub-id pub-id-type="pmcid">PMC8890435</pub-id></element-citation></ref><ref id="B18-ijms-27-00362"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;keefe</surname><given-names>S.J.</given-names></name></person-group><article-title>Diet, microorganisms and their metabolites, and colon cancer</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2016</year><volume>13</volume><fpage>691</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2016.165</pub-id><pub-id pub-id-type="pmid">27848961</pub-id><pub-id pub-id-type="pmcid">PMC6312102</pub-id></element-citation></ref><ref id="B19-ijms-27-00362"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Facchin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bertin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bonazzi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lorenzon</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Barba</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barberio</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zingone</surname><given-names>F.</given-names></name><name name-style="western"><surname>Maniero</surname><given-names>D.</given-names></name><name name-style="western"><surname>Scarpa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruffolo</surname><given-names>C.</given-names></name></person-group><article-title>Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications</article-title><source>Life</source><year>2024</year><volume>14</volume><elocation-id>559</elocation-id><pub-id pub-id-type="doi">10.3390/life14050559</pub-id><pub-id pub-id-type="pmid">38792581</pub-id><pub-id pub-id-type="pmcid">PMC11122327</pub-id></element-citation></ref><ref id="B20-ijms-27-00362"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Den Besten</surname><given-names>G.</given-names></name><name name-style="western"><surname>Van Eunen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Groen</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Venema</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reijngoud</surname><given-names>D.-J.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>B.M.</given-names></name></person-group><article-title>The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism</article-title><source>J. Lipid Res.</source><year>2013</year><volume>54</volume><fpage>2325</fpage><lpage>2340</lpage><pub-id pub-id-type="doi">10.1194/jlr.R036012</pub-id><pub-id pub-id-type="pmid">23821742</pub-id><pub-id pub-id-type="pmcid">PMC3735932</pub-id></element-citation></ref><ref id="B21-ijms-27-00362"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic</article-title><source>Int. J. Oncol.</source><year>2024</year><volume>64</volume><fpage>44</fpage><pub-id pub-id-type="doi">10.3892/ijo.2024.5632</pub-id><pub-id pub-id-type="pmid">38426581</pub-id><pub-id pub-id-type="pmcid">PMC10919761</pub-id></element-citation></ref><ref id="B22-ijms-27-00362"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donohoe</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Holley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Hillhouse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Curry</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Renner</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Greenwalt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>E.P.</given-names></name></person-group><article-title>A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota-and butyrate-dependent manner</article-title><source>Cancer Discov.</source><year>2014</year><volume>4</volume><fpage>1387</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0501</pub-id><pub-id pub-id-type="pmid">25266735</pub-id><pub-id pub-id-type="pmcid">PMC4258155</pub-id></element-citation></ref><ref id="B23-ijms-27-00362"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filippone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casili</surname><given-names>G.</given-names></name><name name-style="western"><surname>Scuderi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Mannino</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lanza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Campolo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Paterniti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Capra</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Colarossi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bonasera</surname><given-names>A.</given-names></name></person-group><article-title>Sodium propionate contributes to tumour cell growth inhibition through PPAR-&#947; signalling</article-title><source>Cancers</source><year>2022</year><volume>15</volume><elocation-id>217</elocation-id><pub-id pub-id-type="doi">10.3390/cancers15010217</pub-id><pub-id pub-id-type="pmid">36612214</pub-id><pub-id pub-id-type="pmcid">PMC9818202</pub-id></element-citation></ref><ref id="B24-ijms-27-00362"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirzaei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Afaghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Babakhani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sohrabi</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Hosseini-Fard</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Babolhavaeji</surname><given-names>K.</given-names></name><name name-style="western"><surname>Akbari</surname><given-names>S.K.A.</given-names></name><name name-style="western"><surname>Yousefimashouf</surname><given-names>R.</given-names></name><name name-style="western"><surname>Karampoor</surname><given-names>S.</given-names></name></person-group><article-title>Role of microbiota-derived short-chain fatty acids in cancer development and prevention</article-title><source>Biomed. Pharmacother.</source><year>2021</year><volume>139</volume><fpage>111619</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111619</pub-id><pub-id pub-id-type="pmid">33906079</pub-id></element-citation></ref><ref id="B25-ijms-27-00362"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name></person-group><article-title>Sodium butyrate combined with docetaxel for the treatment of lung adenocarcinoma A549 cells by targeting Gli1</article-title><source>OncoTargets Ther.</source><year>2020</year><volume>13</volume><fpage>8861</fpage><lpage>8875</lpage><pub-id pub-id-type="doi">10.2147/OTT.S252323</pub-id><pub-id pub-id-type="pmcid">PMC7501530</pub-id><pub-id pub-id-type="pmid">32982280</pub-id></element-citation></ref><ref id="B26-ijms-27-00362"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>W.</given-names></name></person-group><article-title>Combining sodium butyrate with cisplatin increases the apoptosis of gastric cancer in vivo and in vitro via the mitochondrial apoptosis pathway</article-title><source>Front. Pharmacol.</source><year>2021</year><volume>12</volume><elocation-id>708093</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.708093</pub-id><pub-id pub-id-type="pmid">34512341</pub-id><pub-id pub-id-type="pmcid">PMC8430036</pub-id></element-citation></ref><ref id="B27-ijms-27-00362"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geng</surname><given-names>H.-W.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>F.-Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.-F.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>Butyrate suppresses glucose metabolism of colorectal cancer cells via GPR109a-AKT signalling pathway and enhances chemotherapy</article-title><source>Front. Mol. Biosci.</source><year>2021</year><volume>8</volume><elocation-id>634874</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2021.634874</pub-id><pub-id pub-id-type="pmid">33855046</pub-id><pub-id pub-id-type="pmcid">PMC8039130</pub-id></element-citation></ref><ref id="B28-ijms-27-00362"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cristiano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cuozzo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coretti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liguori</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cimmino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Turco</surname><given-names>L.</given-names></name><name name-style="western"><surname>Avagliano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aviello</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mollica</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lembo</surname><given-names>F.</given-names></name></person-group><article-title>Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction</article-title><source>Biomed. Pharmacother.</source><year>2022</year><volume>153</volume><fpage>113528</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113528</pub-id><pub-id pub-id-type="pmid">36076609</pub-id></element-citation></ref><ref id="B29-ijms-27-00362"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maruyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nojima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shima</surname><given-names>H.</given-names></name></person-group><article-title>Apoptosis of bladder cancer by sodium butyrate and cisplatin</article-title><source>J. Infect. Chemother.</source><year>2012</year><volume>18</volume><fpage>288</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1007/s10156-011-0322-2</pub-id><pub-id pub-id-type="pmid">22041988</pub-id></element-citation></ref><ref id="B30-ijms-27-00362"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mikami</surname><given-names>D.</given-names></name><name name-style="western"><surname>Uwada</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yazawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kamiyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Iwano</surname><given-names>M.</given-names></name></person-group><article-title>A short-chain fatty acid, propionate, enhances the cytotoxic effect of cisplatin by modulating GPR41 signalling pathways in HepG2 cells</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>31342</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.25809</pub-id><pub-id pub-id-type="pmid">30140374</pub-id><pub-id pub-id-type="pmcid">PMC6101142</pub-id></element-citation></ref><ref id="B31-ijms-27-00362"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eladwy</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Alsherbiny</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fares</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.-G.</given-names></name><name name-style="western"><surname>Bhuyan</surname><given-names>D.J.</given-names></name></person-group><article-title>The postbiotic sodium butyrate synergizes the antiproliferative effects of dexamethasone against the AGS gastric adenocarcinoma cells</article-title><source>Front. Nutr.</source><year>2024</year><volume>11</volume><elocation-id>1372982</elocation-id><pub-id pub-id-type="doi">10.3389/fnut.2024.1372982</pub-id><pub-id pub-id-type="pmid">38533461</pub-id><pub-id pub-id-type="pmcid">PMC10963608</pub-id></element-citation></ref><ref id="B32-ijms-27-00362"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eladwy</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Fares</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alsherbiny</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.-G.</given-names></name><name name-style="western"><surname>Bhuyan</surname><given-names>D.J.</given-names></name></person-group><article-title>Fuelling the Fight from the Gut: Short-Chain Fatty Acids and Dexamethasone Synergise to Suppress Gastric Cancer Cells</article-title><source>Cancers</source><year>2025</year><volume>17</volume><elocation-id>2486</elocation-id><pub-id pub-id-type="doi">10.3390/cancers17152486</pub-id><pub-id pub-id-type="pmid">40805185</pub-id><pub-id pub-id-type="pmcid">PMC12346683</pub-id></element-citation></ref><ref id="B33-ijms-27-00362"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaye</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alsherbiny</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.-G.</given-names></name><name name-style="western"><surname>Bhuyan</surname><given-names>D.J.</given-names></name></person-group><article-title>Mechanistic insights into the anti-proliferative action of gut microbial metabolites against breast adenocarcinoma cells</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>15053</elocation-id><pub-id pub-id-type="doi">10.3390/ijms242015053</pub-id><pub-id pub-id-type="pmid">37894734</pub-id><pub-id pub-id-type="pmcid">PMC10606851</pub-id></element-citation></ref><ref id="B34-ijms-27-00362"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Semaan</surname><given-names>J.</given-names></name><name name-style="western"><surname>El-Hakim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>J.-N.</given-names></name><name name-style="western"><surname>Safi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Elnar</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>El Boustany</surname><given-names>C.</given-names></name></person-group><article-title>Comparative effect of sodium butyrate and sodium propionate on proliferation, cell cycle and apoptosis in human breast cancer cells MCF-7</article-title><source>Breast Cancer</source><year>2020</year><volume>27</volume><fpage>696</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1007/s12282-020-01063-6</pub-id><pub-id pub-id-type="pmid">32095987</pub-id></element-citation></ref><ref id="B35-ijms-27-00362"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Qadami</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Secombe</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Subramaniam</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Wardill</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Bowen</surname><given-names>J.M.</given-names></name></person-group><article-title>Gut microbiota-derived short-chain fatty acids: Impact on cancer treatment response and toxicities</article-title><source>Microorganisms</source><year>2022</year><volume>10</volume><elocation-id>2048</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms10102048</pub-id><pub-id pub-id-type="pmid">36296324</pub-id><pub-id pub-id-type="pmcid">PMC9612155</pub-id></element-citation></ref><ref id="B36-ijms-27-00362"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thorn</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Oshiro</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hernandez-Boussard</surname><given-names>T.</given-names></name><name name-style="western"><surname>McLeod</surname><given-names>H.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Altman</surname><given-names>R.B.</given-names></name></person-group><article-title>Doxorubicin pathways: Pharmacodynamics and adverse effects</article-title><source>Pharmacogenet. Genom.</source><year>2011</year><volume>21</volume><fpage>440</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1097/FPC.0b013e32833ffb56</pub-id><pub-id pub-id-type="pmid">21048526</pub-id><pub-id pub-id-type="pmcid">PMC3116111</pub-id></element-citation></ref><ref id="B37-ijms-27-00362"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsherbiny</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Radwan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Moustafa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bhuyan</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>El-Waisi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.G.</given-names></name></person-group><article-title>Trustworthy deep neural network for inferring anticancer synergistic combinations</article-title><source>IEEE J. Biomed. Health Inform.</source><year>2021</year><volume>27</volume><fpage>1691</fpage><lpage>1700</lpage><pub-id pub-id-type="doi">10.1109/JBHI.2021.3126339</pub-id><pub-id pub-id-type="pmid">34752413</pub-id></element-citation></ref><ref id="B38-ijms-27-00362"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ozaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakagawara</surname><given-names>A.</given-names></name></person-group><article-title>Role of p53 in cell death and human cancers</article-title><source>Cancers</source><year>2011</year><volume>3</volume><fpage>994</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.3390/cancers3010994</pub-id><pub-id pub-id-type="pmid">24212651</pub-id><pub-id pub-id-type="pmcid">PMC3756401</pub-id></element-citation></ref><ref id="B39-ijms-27-00362"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finsterwald</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alberini</surname><given-names>C.M.</given-names></name></person-group><article-title>Stress and glucocorticoid receptor-dependent mechanisms in long-term memory: From adaptive responses to psychopathologies</article-title><source>Neurobiol. Learn. Mem.</source><year>2014</year><volume>112</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.nlm.2013.09.017</pub-id><pub-id pub-id-type="pmid">24113652</pub-id><pub-id pub-id-type="pmcid">PMC3979509</pub-id></element-citation></ref><ref id="B40-ijms-27-00362"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>C/EBP&#946;: The structure, regulation, and its roles in inflammation-related diseases</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>169</volume><fpage>115938</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2023.115938</pub-id><pub-id pub-id-type="pmid">38000353</pub-id></element-citation></ref><ref id="B41-ijms-27-00362"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237; i L&#237;ndez</surname><given-names>A.-A.</given-names></name><name name-style="western"><surname>Reith</surname><given-names>W.</given-names></name></person-group><article-title>Arginine-dependent immune responses</article-title><source>Cell. Mol. Life Sci.</source><year>2021</year><volume>78</volume><fpage>5303</fpage><lpage>5324</lpage><pub-id pub-id-type="doi">10.1007/s00018-021-03828-4</pub-id><pub-id pub-id-type="pmid">34037806</pub-id><pub-id pub-id-type="pmcid">PMC8257534</pub-id></element-citation></ref><ref id="B42-ijms-27-00362"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>Endonuclease G is an apoptotic DNase when released from mitochondria</article-title><source>Nature</source><year>2001</year><volume>412</volume><fpage>95</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1038/35083620</pub-id><pub-id pub-id-type="pmid">11452314</pub-id></element-citation></ref><ref id="B43-ijms-27-00362"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farooq</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lindb&#230;k</surname><given-names>L.</given-names></name><name name-style="western"><surname>Krogh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Doganli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Keller</surname><given-names>C.</given-names></name><name name-style="western"><surname>M&#246;nnich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gon&#231;alves</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Sakthivel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>A.</given-names></name></person-group><article-title>RRP7A links primary microcephaly to dysfunction of ribosome biogenesis, resorption of primary cilia, and neurogenesis</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>5816</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-19658-0</pub-id><pub-id pub-id-type="pmid">33199730</pub-id><pub-id pub-id-type="pmcid">PMC7670429</pub-id></element-citation></ref><ref id="B44-ijms-27-00362"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Spitale</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Wysocka</surname><given-names>J.</given-names></name></person-group><article-title>RNA helicase DDX21 coordinates transcription and ribosomal RNA processing</article-title><source>Nature</source><year>2015</year><volume>518</volume><fpage>249</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1038/nature13923</pub-id><pub-id pub-id-type="pmid">25470060</pub-id><pub-id pub-id-type="pmcid">PMC4827702</pub-id></element-citation></ref><ref id="B45-ijms-27-00362"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ray Chaudhuri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nussenzweig</surname><given-names>A.</given-names></name></person-group><article-title>The multifaceted roles of PARP1 in DNA repair and chromatin remodelling</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2017</year><volume>18</volume><fpage>610</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.53</pub-id><pub-id pub-id-type="pmid">28676700</pub-id><pub-id pub-id-type="pmcid">PMC6591728</pub-id></element-citation></ref><ref id="B46-ijms-27-00362"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsumura</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kanakura</surname><given-names>Y.</given-names></name></person-group><article-title>E2F1 and c-Myc in cell growth and death</article-title><source>Cell Cycle</source><year>2003</year><volume>2</volume><fpage>332</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.4161/cc.2.4.428</pub-id><pub-id pub-id-type="pmid">12851485</pub-id></element-citation></ref><ref id="B47-ijms-27-00362"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name></person-group><article-title>Oxidative Stress and Reprogramming of Lipid Metabolism in Cancers</article-title><source>Antioxidants</source><year>2025</year><volume>14</volume><elocation-id>201</elocation-id><pub-id pub-id-type="doi">10.3390/antiox14020201</pub-id><pub-id pub-id-type="pmid">40002387</pub-id><pub-id pub-id-type="pmcid">PMC11851681</pub-id></element-citation></ref><ref id="B48-ijms-27-00362"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lathia</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name></person-group><article-title>Overview of cancer stem cells and stemness for community oncologists</article-title><source>Target. Oncol.</source><year>2017</year><volume>12</volume><fpage>387</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1007/s11523-017-0508-3</pub-id><pub-id pub-id-type="pmid">28664387</pub-id><pub-id pub-id-type="pmcid">PMC5524873</pub-id></element-citation></ref><ref id="B49-ijms-27-00362"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C.</given-names></name></person-group><article-title>Downregulated RPL6 inhibits lung cancer cell proliferation and migration and promotes cell apoptosis by regulating the AKT signalling pathway</article-title><source>J. Thorac. Dis.</source><year>2022</year><volume>14</volume><fpage>507</fpage><pub-id pub-id-type="doi">10.21037/jtd-22-116</pub-id><pub-id pub-id-type="pmid">35280491</pub-id><pub-id pub-id-type="pmcid">PMC8902122</pub-id></element-citation></ref><ref id="B50-ijms-27-00362"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Atyah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>High RPS3A expression correlates with low tumour immune cell infiltration and unfavorable prognosis in hepatocellular carcinoma patients</article-title><source>Am. J. Cancer Res.</source><year>2020</year><volume>10</volume><fpage>2768</fpage><pub-id pub-id-type="pmid">33042616</pub-id><pub-id pub-id-type="pmcid">PMC7539769</pub-id></element-citation></ref><ref id="B51-ijms-27-00362"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name></person-group><article-title>High-fat diet promotes prostate cancer metastasis via RPS27</article-title><source>Cancer Metab.</source><year>2024</year><volume>12</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1186/s40170-024-00333-7</pub-id><pub-id pub-id-type="pmid">38365771</pub-id><pub-id pub-id-type="pmcid">PMC10870677</pub-id></element-citation></ref><ref id="B52-ijms-27-00362"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>High expression of RPL27A predicts poor prognosis in patients with hepatocellular carcinoma</article-title><source>World J. Surg. Oncol.</source><year>2023</year><volume>21</volume><fpage>209</fpage><pub-id pub-id-type="doi">10.1186/s12957-023-03102-w</pub-id><pub-id pub-id-type="pmid">37474947</pub-id><pub-id pub-id-type="pmcid">PMC10360225</pub-id></element-citation></ref><ref id="B53-ijms-27-00362"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Molavi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Samadi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hashemzadeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Halimi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hosseingholi</surname><given-names>E.Z.</given-names></name></person-group><article-title>Moonlight human ribosomal protein L13a downregulation is associated with p53 and HER2/neu expression in breast cancer</article-title><source>J. Appl. Biomed.</source><year>2020</year><volume>18</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.32725/jab.2020.008</pub-id><pub-id pub-id-type="pmid">34907725</pub-id></element-citation></ref><ref id="B54-ijms-27-00362"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name></person-group><article-title>Pan-cancer analysis of 60S Ribosomal Protein L7-Like 1 (RPL7L1) and validation in liver hepatocellular carcinoma</article-title><source>Transl. Oncol.</source><year>2024</year><volume>40</volume><fpage>101844</fpage><pub-id pub-id-type="doi">10.1016/j.tranon.2023.101844</pub-id><pub-id pub-id-type="pmid">38042135</pub-id><pub-id pub-id-type="pmcid">PMC10701367</pub-id></element-citation></ref><ref id="B55-ijms-27-00362"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Downregulation of RPL6 by siRNA inhibits proliferation and cell cycle progression of human gastric cancer cell lines</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e26401</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0026401</pub-id><pub-id pub-id-type="pmid">22043320</pub-id><pub-id pub-id-type="pmcid">PMC3197136</pub-id></element-citation></ref><ref id="B56-ijms-27-00362"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>Human ribosomal protein S13 promotes gastric cancer growth through down-regulating p27Kip1</article-title><source>J. Cell. Mol. Med.</source><year>2011</year><volume>15</volume><fpage>296</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00969.x</pub-id><pub-id pub-id-type="pmid">19912438</pub-id><pub-id pub-id-type="pmcid">PMC3822796</pub-id></element-citation></ref><ref id="B57-ijms-27-00362"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dave</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.-B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Granados</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ezzedine</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Sieglaff</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Ensor</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.D.</given-names></name></person-group><article-title>Role of RPL39 in metaplastic breast cancer</article-title><source>J. Natl. Cancer Inst.</source><year>2017</year><volume>109</volume><fpage>djw292</fpage><pub-id pub-id-type="doi">10.1093/jnci/djw292</pub-id><pub-id pub-id-type="pmid">28040796</pub-id><pub-id pub-id-type="pmcid">PMC6245334</pub-id></element-citation></ref><ref id="B58-ijms-27-00362"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao-De</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>X.</given-names></name></person-group><article-title>Ribosomal proteins and colorectal cancer</article-title><source>Curr. Genom.</source><year>2007</year><volume>8</volume><fpage>43</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.2174/138920207780076938</pub-id><pub-id pub-id-type="pmcid">PMC2474683</pub-id><pub-id pub-id-type="pmid">18645623</pub-id></element-citation></ref><ref id="B59-ijms-27-00362"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K.</given-names></name></person-group><article-title>Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis</article-title><source>Exp. Cell Res.</source><year>2004</year><volume>296</volume><fpage>337</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2004.02.009</pub-id><pub-id pub-id-type="pmid">15149863</pub-id></element-citation></ref><ref id="B60-ijms-27-00362"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gambardella</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gimeno-Valiente</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tarazona</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ciarpaglini</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Roda</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fleitas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tolosa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cejalvo</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Huerta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosell&#243;</surname><given-names>S.</given-names></name></person-group><article-title>NRF2 through RPS6 activation is related to anti-HER2 drug resistance in HER2-amplified gastric cancer</article-title><source>Clin. Cancer Res.</source><year>2019</year><volume>25</volume><fpage>1639</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2421</pub-id><pub-id pub-id-type="pmid">30504425</pub-id></element-citation></ref><ref id="B61-ijms-27-00362"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gambardella</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gimeno-Valiente</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tarazona</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kanonnikoff</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Tolosa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moscard&#242;</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Garcia-Mico</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huerta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosell&#243;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roda</surname><given-names>D.</given-names></name></person-group><article-title>NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer</article-title><source>Ann. Oncol.</source><year>2018</year><volume>29</volume><fpage>viii224</fpage><pub-id pub-id-type="doi">10.1093/annonc/mdy282.049</pub-id></element-citation></ref><ref id="B62-ijms-27-00362"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name></person-group><article-title>Expression and bioinformatics analysis of RPL38 protein and mRNA in gastric cancer</article-title><source>Cell. Mol. Biol.</source><year>2023</year><volume>69</volume><fpage>256</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.14715/cmb/2023.69.13.38</pub-id><pub-id pub-id-type="pmid">38158659</pub-id></element-citation></ref><ref id="B63-ijms-27-00362"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.-P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.-X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.-J.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.-X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>Q.-M.</given-names></name></person-group><article-title>Alteration of RPL14 in squamous cell carcinomas and preneoplastic lesions of the esophagus</article-title><source>Gene</source><year>2006</year><volume>366</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2005.09.025</pub-id><pub-id pub-id-type="pmid">16316724</pub-id></element-citation></ref><ref id="B64-ijms-27-00362"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>H.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>R.H.</given-names></name></person-group><article-title>Cellular variability of nonsense-mediated mRNA decay</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>7203</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-27423-0</pub-id><pub-id pub-id-type="pmid">34893608</pub-id><pub-id pub-id-type="pmcid">PMC8664836</pub-id></element-citation></ref><ref id="B65-ijms-27-00362"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuzaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Naito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Miura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T.</given-names></name><name name-style="western"><surname>Watabe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yoshimoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shibahara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Honda</surname><given-names>K.</given-names></name></person-group><article-title>RIOK2 contributes to cell growth and protein synthesis in human oral squamous cell carcinoma</article-title><source>Curr. Oncol.</source><year>2022</year><volume>30</volume><fpage>381</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.3390/curroncol30010031</pub-id><pub-id pub-id-type="pmid">36661680</pub-id><pub-id pub-id-type="pmcid">PMC9857684</pub-id></element-citation></ref><ref id="B66-ijms-27-00362"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Black</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Goering</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>A.W.</given-names></name></person-group><article-title>Utp14 interaction with the small subunit processome</article-title><source>RNA</source><year>2018</year><volume>24</volume><fpage>1214</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1261/rna.066373.118</pub-id><pub-id pub-id-type="pmid">29925570</pub-id><pub-id pub-id-type="pmcid">PMC6097655</pub-id></element-citation></ref><ref id="B67-ijms-27-00362"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name></person-group><article-title>Overexpression of U three protein 14a (UTP14a) is associated with poor prognosis of esophageal squamous cell carcinoma</article-title><source>Thorac. Cancer</source><year>2019</year><volume>10</volume><fpage>2071</fpage><lpage>2080</lpage><pub-id pub-id-type="doi">10.1111/1759-7714.13176</pub-id><pub-id pub-id-type="pmid">31496055</pub-id><pub-id pub-id-type="pmcid">PMC6825924</pub-id></element-citation></ref><ref id="B68-ijms-27-00362"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>G.</given-names></name></person-group><article-title>Hypermethylation and downregulation of UTP6 are associated with stemness properties, chemoradiotherapy resistance, and prognosis in rectal cancer: A co-expression network analysis</article-title><source>Front. Cell Dev. Biol.</source><year>2021</year><volume>9</volume><elocation-id>607782</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.607782</pub-id><pub-id pub-id-type="pmid">34485268</pub-id><pub-id pub-id-type="pmcid">PMC8416280</pub-id></element-citation></ref><ref id="B69-ijms-27-00362"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name></person-group><article-title>DEAD-box helicase 56 functions as an oncogene promote cell proliferation and invasion in gastric cancer via the FOXO1/p21 Cip1/c-Myc signalling pathway</article-title><source>Bioengineered</source><year>2022</year><volume>13</volume><fpage>13970</fpage><lpage>13985</lpage><pub-id pub-id-type="doi">10.1080/21655979.2022.2084235</pub-id><pub-id pub-id-type="pmid">35723050</pub-id><pub-id pub-id-type="pmcid">PMC9275944</pub-id></element-citation></ref><ref id="B70-ijms-27-00362"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Z.</given-names></name></person-group><article-title>RNA-seq and integrated network analysis reveals the hub genes and key pathway of paclitaxel inhibition on Adriamycin resistant diffuse large B cell lymphoma cells</article-title><source>Bioengineered</source><year>2022</year><volume>13</volume><fpage>7607</fpage><lpage>7621</lpage><pub-id pub-id-type="doi">10.1080/21655979.2022.2048772</pub-id><pub-id pub-id-type="pmid">35263200</pub-id><pub-id pub-id-type="pmcid">PMC8973673</pub-id></element-citation></ref><ref id="B71-ijms-27-00362"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>D.</given-names></name></person-group><article-title>NSA2, a novel nucleolus protein regulates cell proliferation and cell cycle</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2010</year><volume>391</volume><fpage>651</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.11.114</pub-id><pub-id pub-id-type="pmid">19932687</pub-id></element-citation></ref><ref id="B72-ijms-27-00362"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Louvet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Oda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kumeta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Horigome</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takeyasu</surname><given-names>K.</given-names></name></person-group><article-title>Nucleolar scaffold protein, WDR 46, determines the granular compartmental localization of nucleolin and DDX 21</article-title><source>Genes Cells</source><year>2013</year><volume>18</volume><fpage>780</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1111/gtc.12077</pub-id><pub-id pub-id-type="pmid">23848194</pub-id></element-citation></ref><ref id="B73-ijms-27-00362"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paternoga</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fr&#252;h</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kunze</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bradatsch</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ba&#223;ler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hurt</surname><given-names>E.</given-names></name></person-group><article-title>Mutational analysis of the Nsa2 N-terminus reveals its essential role in ribosomal 60S subunit assembly</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>9108</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21239108</pub-id><pub-id pub-id-type="pmid">33266193</pub-id><pub-id pub-id-type="pmcid">PMC7730687</pub-id></element-citation></ref><ref id="B74-ijms-27-00362"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaremba</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>M.</given-names></name><name name-style="western"><surname>Plummer</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Curtin</surname><given-names>N.J.</given-names></name></person-group><article-title>Doxorubicin-induced suppression of poly (ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials</article-title><source>Cancer Chemother. Pharmacol.</source><year>2010</year><volume>66</volume><fpage>807</fpage><lpage>812</lpage><pub-id pub-id-type="doi">10.1007/s00280-010-1359-0</pub-id><pub-id pub-id-type="pmid">20490796</pub-id></element-citation></ref><ref id="B75-ijms-27-00362"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Luca</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vazquez</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Moiola</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Zalazar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cotignola</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gueron</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>K.</given-names></name><name name-style="western"><surname>De Siervi</surname><given-names>A.</given-names></name></person-group><article-title>BRCA1 loss induces GADD153-mediated doxorubicin resistance in prostate cancer</article-title><source>Mol. Cancer Res.</source><year>2011</year><volume>9</volume><fpage>1078</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-11-0155</pub-id><pub-id pub-id-type="pmid">21700680</pub-id><pub-id pub-id-type="pmcid">PMC6959536</pub-id></element-citation></ref><ref id="B76-ijms-27-00362"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Z.</given-names></name></person-group><article-title>RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer</article-title><source>Cancer Cell Int.</source><year>2019</year><volume>19</volume><fpage>356</fpage><pub-id pub-id-type="doi">10.1186/s12935-019-1077-6</pub-id><pub-id pub-id-type="pmid">31889908</pub-id><pub-id pub-id-type="pmcid">PMC6935217</pub-id></element-citation></ref><ref id="B77-ijms-27-00362"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Busatto</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Viero</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Saffi</surname><given-names>J.</given-names></name></person-group><article-title>Cell growth analysis and nucleotide excision repair modulation in breast cancer cells submitted to a protocol using doxorubicin and paclitaxel</article-title><source>Life Sci.</source><year>2021</year><volume>268</volume><fpage>118990</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2020.118990</pub-id><pub-id pub-id-type="pmid">33412214</pub-id></element-citation></ref><ref id="B78-ijms-27-00362"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Foronda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blasco</surname><given-names>M.A.</given-names></name></person-group><article-title>Conditional TRF1 knockout in the hematopoietic compartment leads to bone marrow failure and recapitulates clinical features of dyskeratosis congenita</article-title><source>Blood J. Am. Soc. Hematol.</source><year>2012</year><volume>120</volume><fpage>2990</fpage><lpage>3000</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-03-418038</pub-id><pub-id pub-id-type="pmcid">PMC3918664</pub-id><pub-id pub-id-type="pmid">22932806</pub-id></element-citation></ref><ref id="B79-ijms-27-00362"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Garrobo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Foronda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Palacios</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Mari&#243;n</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Flores</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blasco</surname><given-names>M.A.</given-names></name></person-group><article-title>TRF1 is a stem cell marker and is essential for the generation of induced pluripotent stem cells</article-title><source>Nat. Commun.</source><year>2013</year><volume>4</volume><fpage>1946</fpage><comment>Erratum in <italic toggle="yes">Nat. Commun.</italic><bold>2013</bold>, <italic toggle="yes">4</italic>, 2309</comment><pub-id pub-id-type="doi">10.1038/ncomms2946</pub-id><pub-id pub-id-type="pmid">23735977</pub-id></element-citation></ref><ref id="B80-ijms-27-00362"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lugli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sotiriou</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Halazonetis</surname><given-names>T.D.</given-names></name></person-group><article-title>The role of SMARCAL1 in replication fork stability and telomere maintenance</article-title><source>DNA Repair</source><year>2017</year><volume>56</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2017.06.015</pub-id><pub-id pub-id-type="pmid">28623093</pub-id></element-citation></ref><ref id="B81-ijms-27-00362"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Workman</surname><given-names>J.L.</given-names></name></person-group><article-title>Elevated levels of the methyltransferase SETD2 causes transcription and alternative splicing changes resulting in oncogenic phenotypes</article-title><source>Front. Cell Dev. Biol.</source><year>2022</year><volume>10</volume><elocation-id>945668</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.945668</pub-id><pub-id pub-id-type="pmid">36035998</pub-id><pub-id pub-id-type="pmcid">PMC9399737</pub-id></element-citation></ref><ref id="B82-ijms-27-00362"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mar</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Krivtsov</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Koche</surname><given-names>R.</given-names></name><name name-style="western"><surname>Castellano</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Kotlier</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Zon</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>McConkey</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Chabon</surname><given-names>J.</given-names></name></person-group><article-title>SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia</article-title><source>Blood J. Am. Soc. Hematol.</source><year>2017</year><volume>130</volume><fpage>2631</fpage><lpage>2641</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-03-775569</pub-id><pub-id pub-id-type="pmcid">PMC5731084</pub-id><pub-id pub-id-type="pmid">29018079</pub-id></element-citation></ref><ref id="B83-ijms-27-00362"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>G.</given-names></name></person-group><article-title>Expression of MUC1 in different tumours and its clinical significance</article-title><source>Mol. Clin. Oncol.</source><year>2022</year><volume>17</volume><fpage>161</fpage><pub-id pub-id-type="doi">10.3892/mco.2022.2594</pub-id><pub-id pub-id-type="pmid">36479256</pub-id><pub-id pub-id-type="pmcid">PMC9716114</pub-id></element-citation></ref><ref id="B84-ijms-27-00362"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>B.</given-names></name></person-group><article-title>Elevated expression of Axin2 in intestinal metaplasia and gastric cancers</article-title><source>J. Pathol. Transl. Med.</source><year>2023</year><volume>57</volume><fpage>315</fpage><pub-id pub-id-type="doi">10.4132/jptm.2023.10.12</pub-id><pub-id pub-id-type="pmid">37926983</pub-id><pub-id pub-id-type="pmcid">PMC10660364</pub-id></element-citation></ref><ref id="B85-ijms-27-00362"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>B.</given-names></name></person-group><article-title>Inhibition of MGMT-mediated autophagy suppression decreases cisplatin chemosensitivity in gastric cancer</article-title><source>Biomed. Pharmacother.</source><year>2020</year><volume>125</volume><fpage>109896</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2020.109896</pub-id><pub-id pub-id-type="pmid">32007918</pub-id></element-citation></ref><ref id="B86-ijms-27-00362"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.-I.</given-names></name><name name-style="western"><surname>Pecha</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Keihanian</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mercado</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pena-Munoz</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Van Buren</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dhingra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Othman</surname><given-names>M.O.</given-names></name></person-group><article-title>MUC1 expressions and its prognostic values in US gastric cancer patients</article-title><source>Cancers</source><year>2023</year><volume>15</volume><elocation-id>998</elocation-id><pub-id pub-id-type="doi">10.3390/cancers15040998</pub-id><pub-id pub-id-type="pmid">36831343</pub-id><pub-id pub-id-type="pmcid">PMC9954699</pub-id></element-citation></ref><ref id="B87-ijms-27-00362"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nepal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Che</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fei</surname><given-names>P.</given-names></name></person-group><article-title>Fanconi anemia signalling and cancer</article-title><source>Trends Cancer</source><year>2017</year><volume>3</volume><fpage>840</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2017.10.005</pub-id><pub-id pub-id-type="pmid">29198440</pub-id><pub-id pub-id-type="pmcid">PMC5819365</pub-id></element-citation></ref><ref id="B88-ijms-27-00362"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tripathi</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Biswal</surname><given-names>B.K.</given-names></name></person-group><article-title>SOX9: An emerging driving factor from cancer progression to drug resistance</article-title><source>Biochim. Biophys. Acta (BBA) Rev. Cancer</source><year>2021</year><volume>1875</volume><fpage>188517</fpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2021.188517</pub-id><pub-id pub-id-type="pmid">33524528</pub-id></element-citation></ref><ref id="B89-ijms-27-00362"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gooch</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Christy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>D.</given-names></name></person-group><article-title>STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells</article-title><source>Neoplasia</source><year>2002</year><volume>4</volume><fpage>324</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1038/sj.neo.7900248</pub-id><pub-id pub-id-type="pmid">12082548</pub-id><pub-id pub-id-type="pmcid">PMC1531710</pub-id></element-citation></ref><ref id="B90-ijms-27-00362"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>F.</given-names></name></person-group><article-title>E3 ubiquitin ligase SYVN1 is a key positive regulator for GSDMD-mediated pyroptosis</article-title><source>Cell Death Dis.</source><year>2022</year><volume>13</volume><fpage>106</fpage><pub-id pub-id-type="doi">10.1038/s41419-022-04553-x</pub-id><pub-id pub-id-type="pmid">35115505</pub-id><pub-id pub-id-type="pmcid">PMC8814081</pub-id></element-citation></ref><ref id="B91-ijms-27-00362"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>GINS2 regulates the proliferation and apoptosis of colon cancer cells through PTP4A1</article-title><source>Mol. Med. Rep.</source><year>2022</year><volume>25</volume><fpage>117</fpage><pub-id pub-id-type="doi">10.3892/mmr.2022.12633</pub-id><pub-id pub-id-type="pmid">35137928</pub-id><pub-id pub-id-type="pmcid">PMC8855163</pub-id></element-citation></ref><ref id="B92-ijms-27-00362"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Sartor</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>R.J.</given-names></name></person-group><article-title>Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma</article-title><source>J. Biol. Chem.</source><year>2020</year><volume>295</volume><fpage>8834</fpage><lpage>8845</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.013530</pub-id><pub-id pub-id-type="pmid">32398261</pub-id><pub-id pub-id-type="pmcid">PMC7324504</pub-id></element-citation></ref><ref id="B93-ijms-27-00362"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nardone</surname><given-names>V.</given-names></name><name name-style="western"><surname>Barbarino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Angrisani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Correale</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pastina</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cappabianca</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reginelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mutti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Miracco</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giannicola</surname><given-names>R.</given-names></name></person-group><article-title>CDK4, CDK6/cyclin-D1 complex inhibition and radiotherapy for cancer control: A role for autophagy</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>8391</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22168391</pub-id><pub-id pub-id-type="pmid">34445095</pub-id><pub-id pub-id-type="pmcid">PMC8395054</pub-id></element-citation></ref><ref id="B94-ijms-27-00362"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fassl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sicinski</surname><given-names>P.</given-names></name></person-group><article-title>CDK4 and CDK6 kinases: From basic science to cancer therapy</article-title><source>Science</source><year>2022</year><volume>375</volume><fpage>eabc1495</fpage><pub-id pub-id-type="doi">10.1126/science.abc1495</pub-id><pub-id pub-id-type="pmid">35025636</pub-id><pub-id pub-id-type="pmcid">PMC9048628</pub-id></element-citation></ref><ref id="B95-ijms-27-00362"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chimploy</surname><given-names>K.</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>O.</given-names></name><name name-style="western"><surname>Dashwood</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Dashwood</surname><given-names>R.H.</given-names></name></person-group><article-title>E2F4 and ribonucleotide reductase mediate S-phase arrest in colon cancer cells treated with chlorophyllin</article-title><source>Int. J. Cancer</source><year>2009</year><volume>125</volume><fpage>2086</fpage><lpage>2094</lpage><pub-id pub-id-type="doi">10.1002/ijc.24559</pub-id><pub-id pub-id-type="pmid">19585502</pub-id><pub-id pub-id-type="pmcid">PMC2753276</pub-id></element-citation></ref><ref id="B96-ijms-27-00362"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engeland</surname><given-names>K.</given-names></name></person-group><article-title>Cell cycle regulation: P53-p21-RB signalling</article-title><source>Cell Death Differ.</source><year>2022</year><volume>29</volume><fpage>946</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1038/s41418-022-00988-z</pub-id><pub-id pub-id-type="pmid">35361964</pub-id><pub-id pub-id-type="pmcid">PMC9090780</pub-id></element-citation></ref><ref id="B97-ijms-27-00362"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jardim</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Millis</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>M.S.A.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group><article-title>Cyclin pathway genomic alterations across 190,247 solid tumors: Leveraging large-scale data to inform therapeutic directions</article-title><source>Oncologist</source><year>2021</year><volume>26</volume><fpage>e78</fpage><lpage>e89</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2020-0509</pub-id><pub-id pub-id-type="pmid">32885893</pub-id><pub-id pub-id-type="pmcid">PMC7794175</pub-id></element-citation></ref><ref id="B98-ijms-27-00362"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.S.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>H.</given-names></name></person-group><article-title>Cell-cycle-regulated interaction between Mcm10 and double hexameric Mcm2-7 is required for helicase splitting and activation during S phase</article-title><source>Cell Rep.</source><year>2015</year><volume>13</volume><fpage>2576</fpage><lpage>2586</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.11.018</pub-id><pub-id pub-id-type="pmid">26686640</pub-id><pub-id pub-id-type="pmcid">PMC5536962</pub-id></element-citation></ref><ref id="B99-ijms-27-00362"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malkas</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Abdel-Aziz</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dobrolecki</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hoelz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Badve</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schnaper</surname><given-names>L.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>R.J.</given-names></name></person-group><article-title>A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>19472</fpage><lpage>19477</lpage><pub-id pub-id-type="doi">10.1073/pnas.0604614103</pub-id><pub-id pub-id-type="pmid">17159154</pub-id><pub-id pub-id-type="pmcid">PMC1697829</pub-id></element-citation></ref><ref id="B100-ijms-27-00362"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lukas</surname><given-names>J.</given-names></name></person-group><article-title>Chk1 and Chk2 kinases in checkpoint control and cancer</article-title><source>Cancer Cell</source><year>2003</year><volume>3</volume><fpage>421</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(03)00110-7</pub-id><pub-id pub-id-type="pmid">12781359</pub-id></element-citation></ref><ref id="B101-ijms-27-00362"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouery</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Lukasik</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bonacci</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bolhuis</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Toomer</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Canterbury</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>K.C.</given-names></name></person-group><article-title>Proteomic analysis reveals a PLK1-dependent G2/M degradation program and a role for AKAP2 in coordinating the mitotic cytoskeleton</article-title><source>Cell Rep.</source><year>2024</year><volume>43</volume><fpage>114510</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2024.114510</pub-id><pub-id pub-id-type="pmid">39018246</pub-id><pub-id pub-id-type="pmcid">PMC11403584</pub-id></element-citation></ref><ref id="B102-ijms-27-00362"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yoshikawa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ashida</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kirikae</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Kotani</surname><given-names>S.</given-names></name></person-group><article-title>A bacterial effector targets Mad2L2, an APC inhibitor, to modulate host cell cycling</article-title><source>Cell</source><year>2007</year><volume>130</volume><fpage>611</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.06.043</pub-id><pub-id pub-id-type="pmid">17719540</pub-id></element-citation></ref><ref id="B103-ijms-27-00362"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malureanu</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Jeganathan</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Hamada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wasilewski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Davenport</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Deursen</surname><given-names>J.M.</given-names></name></person-group><article-title>BubR1 N terminus acts as a soluble inhibitor of cyclin B degradation by APC/CCdc20 in interphase</article-title><source>Dev. Cell</source><year>2009</year><volume>16</volume><fpage>118</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2008.11.004</pub-id><pub-id pub-id-type="pmid">19154723</pub-id><pub-id pub-id-type="pmcid">PMC2659634</pub-id></element-citation></ref><ref id="B104-ijms-27-00362"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Park</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Sheen</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.H.</given-names></name></person-group><article-title>Expression of anaphase-promoting complex7 in fibroadenomas and phyllodes tumors of breast</article-title><source>Hum. Pathol.</source><year>2009</year><volume>40</volume><fpage>98</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2008.04.023</pub-id><pub-id pub-id-type="pmid">18789487</pub-id></element-citation></ref><ref id="B105-ijms-27-00362"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>L.-J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>C.-P.</given-names></name><name name-style="western"><surname>Jhan</surname><given-names>J.-R.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>L.-C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>P.-J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.-J.</given-names></name></person-group><article-title>Overexpression of the pituitary tumour transforming gene induces p53-dependent senescence through activating DNA damage response pathway in normal human fibroblasts</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>22630</fpage><lpage>22638</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.096255</pub-id><pub-id pub-id-type="pmid">20452981</pub-id><pub-id pub-id-type="pmcid">PMC2903424</pub-id></element-citation></ref><ref id="B106-ijms-27-00362"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marei</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Althani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Afifi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caceci</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pozzoli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Morrione</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cenciarelli</surname><given-names>C.</given-names></name></person-group><article-title>p53 signalling in cancer progression and therapy</article-title><source>Cancer Cell Int.</source><year>2021</year><volume>21</volume><fpage>703</fpage><pub-id pub-id-type="doi">10.1186/s12935-021-02396-8</pub-id><pub-id pub-id-type="pmid">34952583</pub-id><pub-id pub-id-type="pmcid">PMC8709944</pub-id></element-citation></ref><ref id="B107-ijms-27-00362"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.-X.</given-names></name><name name-style="western"><surname>Diao</surname><given-names>T.-Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.-L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.-Q.</given-names></name></person-group><article-title>Implications of the NDC80 complex on the tumour immune microenvironment and cell growth in pan-cancer</article-title><source>J. Cancer</source><year>2024</year><volume>15</volume><fpage>6364</fpage><pub-id pub-id-type="doi">10.7150/jca.96070</pub-id><pub-id pub-id-type="pmid">39513104</pub-id><pub-id pub-id-type="pmcid">PMC11540516</pub-id></element-citation></ref><ref id="B108-ijms-27-00362"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name></person-group><article-title>ESPL1 is a novel prognostic biomarker associated with the malignant features of glioma</article-title><source>Front. Genet.</source><year>2021</year><volume>12</volume><elocation-id>666106</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2021.666106</pub-id><pub-id pub-id-type="pmid">34512713</pub-id><pub-id pub-id-type="pmcid">PMC8428966</pub-id></element-citation></ref><ref id="B109-ijms-27-00362"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>Y.-Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W.-H.</given-names></name></person-group><article-title>HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer</article-title><source>Lung Cancer</source><year>2011</year><volume>74</volume><fpage>504</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2011.04.006</pub-id><pub-id pub-id-type="pmid">21561677</pub-id></element-citation></ref><ref id="B110-ijms-27-00362"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name></person-group><article-title>miR-107 inhibits the proliferation of gastric cancer cells in vivo and in vitro by targeting TRIAP1</article-title><source>Front. Genet.</source><year>2022</year><volume>13</volume><elocation-id>855355</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2022.855355</pub-id><pub-id pub-id-type="pmid">35480301</pub-id><pub-id pub-id-type="pmcid">PMC9035523</pub-id></element-citation></ref><ref id="B111-ijms-27-00362"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Sennhenn</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taddei</surname><given-names>D.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>W.</given-names></name></person-group><article-title>TMBIM6/BI-1 is an intracellular environmental regulator that induces paraptosis in cancer via ROS and Calcium-activated ERAD II pathways</article-title><source>Oncogene</source><year>2025</year><volume>44</volume><fpage>494</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1038/s41388-024-03222-x</pub-id><pub-id pub-id-type="pmid">39609612</pub-id><pub-id pub-id-type="pmcid">PMC11832424</pub-id></element-citation></ref><ref id="B112-ijms-27-00362"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group><article-title>Bleomycin alters intratumoral immune response of EBV-associated gastric cancer by ENTPD8 and PCOLCE2</article-title><source>Preprint</source><year>2023</year><pub-id pub-id-type="doi">10.21203/rs.3.rs-2958586/v1</pub-id></element-citation></ref><ref id="B113-ijms-27-00362"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.-Z.</given-names></name><name name-style="western"><surname>Ann</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.L.-Y.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>C.-Y.</given-names></name></person-group><article-title>Obesity promotes radioresistance through SERPINE1-mediated aggressiveness and DNA repair of triple-negative breast cancer</article-title><source>Cell Death Dis.</source><year>2023</year><volume>14</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1038/s41419-023-05576-8</pub-id><pub-id pub-id-type="pmid">36681663</pub-id><pub-id pub-id-type="pmcid">PMC9867751</pub-id></element-citation></ref><ref id="B114-ijms-27-00362"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de La Vega</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kelvin</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Dunican</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>McFarlane</surname><given-names>C.</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Jaworski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Dib</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rappoport</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>C.J.</given-names></name></person-group><article-title>The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility</article-title><source>Nat. Commun.</source><year>2011</year><volume>2</volume><fpage>259</fpage><pub-id pub-id-type="doi">10.1038/ncomms1243</pub-id><pub-id pub-id-type="pmid">21448158</pub-id><pub-id pub-id-type="pmcid">PMC3072070</pub-id></element-citation></ref><ref id="B115-ijms-27-00362"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>H.</given-names></name></person-group><article-title>CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer</article-title><source>BMC Med. Genom.</source><year>2022</year><volume>15</volume><elocation-id>225</elocation-id><pub-id pub-id-type="doi">10.1186/s12920-022-01383-w</pub-id><pub-id pub-id-type="pmcid">PMC9620622</pub-id><pub-id pub-id-type="pmid">36316684</pub-id></element-citation></ref><ref id="B116-ijms-27-00362"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishina</surname><given-names>H.</given-names></name><name name-style="western"><surname>Inageda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hoshino</surname><given-names>S.-i.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Katada</surname><given-names>T.</given-names></name></person-group><article-title>Cell surface antigen CD38 identified as ecto-enzyme of NAD glycohydrolase has hyaluronate-binding activity</article-title><source>Biochem. Biophys. Res. Commun.</source><year>1994</year><volume>203</volume><fpage>1318</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1994.2326</pub-id><pub-id pub-id-type="pmid">8093047</pub-id></element-citation></ref><ref id="B117-ijms-27-00362"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>Fibrogenesis-driven tumour progression in clear cell renal cell carcinoma: Prognostic, therapeutic implications and the dual role of neuropilin-1</article-title><source>Cancer Cell Int.</source><year>2025</year><volume>25</volume><fpage>179</fpage><pub-id pub-id-type="doi">10.1186/s12935-025-03801-2</pub-id><pub-id pub-id-type="pmid">40380175</pub-id><pub-id pub-id-type="pmcid">PMC12082889</pub-id></element-citation></ref><ref id="B118-ijms-27-00362"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subbalakshmi</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Sahoo</surname><given-names>S.</given-names></name><name name-style="western"><surname>McMullen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Saxena</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Venugopal</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Somarelli</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Jolly</surname><given-names>M.K.</given-names></name></person-group><article-title>KLF4 induces mesenchymal&#8211;epithelial transition (MET) by suppressing multiple EMT-inducing transcription factors</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>5135</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13205135</pub-id><pub-id pub-id-type="pmid">34680284</pub-id><pub-id pub-id-type="pmcid">PMC8533753</pub-id></element-citation></ref><ref id="B119-ijms-27-00362"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baj</surname><given-names>J.</given-names></name><name name-style="western"><surname>Korona-G&#322;owniak</surname><given-names>I.</given-names></name><name name-style="western"><surname>Forma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sitarz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rahnama-Hezavah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Radzikowska</surname><given-names>E.</given-names></name><name name-style="western"><surname>Portincasa</surname><given-names>P.</given-names></name></person-group><article-title>Mechanisms of the epithelial&#8211;mesenchymal transition and tumour microenvironment in Helicobacter pylori-induced gastric cancer</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>1055</elocation-id><pub-id pub-id-type="doi">10.3390/cells9041055</pub-id><pub-id pub-id-type="pmid">32340207</pub-id><pub-id pub-id-type="pmcid">PMC7225971</pub-id></element-citation></ref><ref id="B120-ijms-27-00362"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hoyle</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zaman</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>CYTOR facilitates formation of FOSL1 phase separation and super enhancers to drive metastasis of tumour budding cells in head and neck squamous cell carcinoma</article-title><source>Adv. Sci.</source><year>2024</year><volume>11</volume><fpage>2305002</fpage><pub-id pub-id-type="doi">10.1002/advs.202305002</pub-id><pub-id pub-id-type="pmid">38032139</pub-id><pub-id pub-id-type="pmcid">PMC10811474</pub-id></element-citation></ref><ref id="B121-ijms-27-00362"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kciuk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gieleci&#324;ska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mujwar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ko&#322;at</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ka&#322;uzi&#324;ska-Ko&#322;at</surname><given-names>&#379;.</given-names></name><name name-style="western"><surname>Celik</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kontek</surname><given-names>R.</given-names></name></person-group><article-title>Doxorubicin&#8212;An agent with multiple mechanisms of anticancer activity</article-title><source>Cells</source><year>2023</year><volume>12</volume><elocation-id>659</elocation-id><pub-id pub-id-type="doi">10.3390/cells12040659</pub-id><pub-id pub-id-type="pmid">36831326</pub-id><pub-id pub-id-type="pmcid">PMC9954613</pub-id></element-citation></ref><ref id="B122-ijms-27-00362"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jan</surname><given-names>R.</given-names></name></person-group><article-title>Understanding apoptosis and apoptotic pathways targeted cancer therapeutics</article-title><source>Adv. Pharm. Bull.</source><year>2019</year><volume>9</volume><fpage>205</fpage><pub-id pub-id-type="doi">10.15171/apb.2019.024</pub-id><pub-id pub-id-type="pmid">31380246</pub-id><pub-id pub-id-type="pmcid">PMC6664112</pub-id></element-citation></ref><ref id="B123-ijms-27-00362"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmore</surname><given-names>S.</given-names></name></person-group><article-title>Apoptosis: A review of programmed cell death</article-title><source>Toxicol. Pathol.</source><year>2007</year><volume>35</volume><fpage>495</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1080/01926230701320337</pub-id><pub-id pub-id-type="pmid">17562483</pub-id><pub-id pub-id-type="pmcid">PMC2117903</pub-id></element-citation></ref><ref id="B124-ijms-27-00362"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>S.</given-names></name></person-group><article-title>BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance</article-title><source>Autophagy</source><year>2015</year><volume>11</volume><fpage>416</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1080/15548627.2014.998892</pub-id><pub-id pub-id-type="pmid">25700997</pub-id><pub-id pub-id-type="pmcid">PMC4502657</pub-id></element-citation></ref><ref id="B125-ijms-27-00362"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>H.-K.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gim</surname><given-names>J.-E.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mun</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.-W.</given-names></name></person-group><article-title>CASP9 (caspase 9) is essential for autophagosome maturation through regulation of mitochondrial homeostasis</article-title><source>Autophagy</source><year>2020</year><volume>16</volume><fpage>1598</fpage><lpage>1617</lpage><pub-id pub-id-type="doi">10.1080/15548627.2019.1695398</pub-id><pub-id pub-id-type="pmid">31818185</pub-id><pub-id pub-id-type="pmcid">PMC8386608</pub-id></element-citation></ref><ref id="B126-ijms-27-00362"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weiher</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schmidt-Wolf</surname><given-names>I.G.</given-names></name></person-group><article-title>Biological mechanisms and clinical significance of endoplasmic reticulum oxidoreductase 1 alpha (ERO1&#945;) in human cancer</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2024</year><volume>43</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/s13046-024-02990-4</pub-id><pub-id pub-id-type="pmid">38454454</pub-id><pub-id pub-id-type="pmcid">PMC10921667</pub-id></element-citation></ref><ref id="B127-ijms-27-00362"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>S.J.</given-names></name></person-group><article-title>Nuclear endonuclease G controls cell proliferation in ovarian cancer</article-title><source>FEBS Open Bio</source><year>2023</year><volume>13</volume><fpage>655</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.13572</pub-id><pub-id pub-id-type="pmid">36734593</pub-id><pub-id pub-id-type="pmcid">PMC10068316</pub-id></element-citation></ref><ref id="B128-ijms-27-00362"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oyang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>S.</given-names></name></person-group><article-title>Endoplasmic reticulum stress&#8212;A key guardian in cancer</article-title><source>Cell Death Discov.</source><year>2024</year><volume>10</volume><fpage>343</fpage><pub-id pub-id-type="doi">10.1038/s41420-024-02110-3</pub-id><pub-id pub-id-type="pmid">39080273</pub-id><pub-id pub-id-type="pmcid">PMC11289465</pub-id></element-citation></ref><ref id="B129-ijms-27-00362"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>X.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Tajiknia</surname><given-names>V.</given-names></name><name name-style="western"><surname>Uruchurtu</surname><given-names>A.F.S.S.</given-names></name><name name-style="western"><surname>Seyhan</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Carneiro</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>De La Cruz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pinho-Schwermann</surname><given-names>M.</given-names></name><name name-style="western"><surname>George</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name></person-group><article-title>Targeting apoptotic pathways for cancer therapy</article-title><source>J. Clin. Invest.</source><year>2024</year><volume>134</volume><fpage>e179570</fpage><comment>Corrigendum in <italic toggle="yes">J. Clin. Invest.</italic><bold>2025</bold>, <italic toggle="yes">135</italic>, e196275</comment><pub-id pub-id-type="doi">10.1172/JCI179570</pub-id><pub-id pub-id-type="pmid">39007268</pub-id><pub-id pub-id-type="pmcid">PMC11245162</pub-id></element-citation></ref><ref id="B130-ijms-27-00362"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pobezinskaya</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>The role of TRADD in death receptor signalling</article-title><source>Cell Cycle</source><year>2012</year><volume>11</volume><fpage>871</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.4161/cc.11.5.19300</pub-id><pub-id pub-id-type="pmid">22333735</pub-id><pub-id pub-id-type="pmcid">PMC3679287</pub-id></element-citation></ref><ref id="B131-ijms-27-00362"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bossy-Wetzel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bakiri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yaniv</surname><given-names>M.</given-names></name></person-group><article-title>Induction of apoptosis by the transcription factor c-Jun</article-title><source>EMBO J.</source><year>1997</year><volume>16</volume><fpage>1695</fpage><lpage>1709</lpage><pub-id pub-id-type="doi">10.1093/emboj/16.7.1695</pub-id><pub-id pub-id-type="pmid">9130714</pub-id><pub-id pub-id-type="pmcid">PMC1169773</pub-id></element-citation></ref><ref id="B132-ijms-27-00362"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>Targeting p53 pathways: Mechanisms, structures, and advances in therapy</article-title><source>Signal Transduct. Target. Ther.</source><year>2023</year><volume>8</volume><fpage>92</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01347-1</pub-id><pub-id pub-id-type="pmid">36859359</pub-id><pub-id pub-id-type="pmcid">PMC9977964</pub-id></element-citation></ref><ref id="B133-ijms-27-00362"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Madry</surname><given-names>C.</given-names></name><name name-style="western"><surname>Buhard</surname><given-names>O.</given-names></name><name name-style="western"><surname>Toifl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Didusch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ratovomanana</surname><given-names>T.</given-names></name><name name-style="western"><surname>Letourneur</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dolznig</surname><given-names>H.</given-names></name><name name-style="western"><surname>Garnett</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Duval</surname><given-names>A.</given-names></name></person-group><article-title>RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status</article-title><source>Oncogene</source><year>2023</year><volume>42</volume><fpage>1649</fpage><lpage>1660</lpage><pub-id pub-id-type="doi">10.1038/s41388-023-02683-w</pub-id><pub-id pub-id-type="pmid">37020037</pub-id><pub-id pub-id-type="pmcid">PMC10181936</pub-id></element-citation></ref><ref id="B134-ijms-27-00362"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aubrey</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Janic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Herold</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Strasser</surname><given-names>A.</given-names></name></person-group><article-title>How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?</article-title><source>Cell Death Differ</source><year>2018</year><volume>25</volume><fpage>104</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/cdd.2017.169</pub-id><pub-id pub-id-type="pmid">29149101</pub-id><pub-id pub-id-type="pmcid">PMC5729529</pub-id></element-citation></ref><ref id="B135-ijms-27-00362"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nechiporuk</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kurtz</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Nikolova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>D&#8217;Alessandro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Culp-Hill</surname><given-names>R.</given-names></name><name name-style="western"><surname>d&#8217;Almeida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>M.</given-names></name></person-group><article-title>The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells</article-title><source>Cancer Discov.</source><year>2019</year><volume>9</volume><fpage>910</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-0125</pub-id><pub-id pub-id-type="pmid">31048320</pub-id><pub-id pub-id-type="pmcid">PMC6606338</pub-id></element-citation></ref><ref id="B136-ijms-27-00362"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Le</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name></person-group><article-title>Autophagy is induced through the ROS-TP53-DRAM1 pathway in response to mitochondrial protein synthesis inhibition</article-title><source>Autophagy</source><year>2012</year><volume>8</volume><fpage>1071</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.4161/auto.20250</pub-id><pub-id pub-id-type="pmid">22576012</pub-id><pub-id pub-id-type="pmcid">PMC3429544</pub-id></element-citation></ref><ref id="B137-ijms-27-00362"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Elf</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sashida</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Di Giandomenico</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Deblasio</surname><given-names>A.</given-names></name><name name-style="western"><surname>Menendez</surname><given-names>S.</given-names></name></person-group><article-title>p53 regulates hematopoietic stem cell quiescence</article-title><source>Cell Stem Cell</source><year>2009</year><volume>4</volume><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2008.11.006</pub-id><pub-id pub-id-type="pmid">19128791</pub-id><pub-id pub-id-type="pmcid">PMC2839936</pub-id></element-citation></ref><ref id="B138-ijms-27-00362"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kruse</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name></person-group><article-title>p53 aerobics: The major tumour suppressor fuels your workout</article-title><source>Cell Metab.</source><year>2006</year><volume>4</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2006.06.004</pub-id><pub-id pub-id-type="pmid">16814724</pub-id></element-citation></ref><ref id="B139-ijms-27-00362"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bensaad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tsuruta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Selak</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>M.N.C.</given-names></name><name name-style="western"><surname>Nakano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bartrons</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vousden</surname><given-names>K.H.</given-names></name></person-group><article-title>TIGAR, a p53-inducible regulator of glycolysis and apoptosis</article-title><source>Cell</source><year>2006</year><volume>126</volume><fpage>107</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.05.036</pub-id><pub-id pub-id-type="pmid">16839880</pub-id></element-citation></ref><ref id="B140-ijms-27-00362"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name></person-group><article-title>Human/eukaryotic ribosomal protein L14 (RPL14/eL14) overexpression represses proliferation, migration, invasion and EMT process in nasopharyngeal carcinoma</article-title><source>Bioengineered</source><year>2021</year><volume>12</volume><fpage>2175</fpage><lpage>2186</lpage><pub-id pub-id-type="doi">10.1080/21655979.2021.1932225</pub-id><pub-id pub-id-type="pmid">34057029</pub-id><pub-id pub-id-type="pmcid">PMC8806664</pub-id></element-citation></ref><ref id="B141-ijms-27-00362"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mart&#237;n-Villanueva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guti&#233;rrez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kressler</surname><given-names>D.</given-names></name><name name-style="western"><surname>de la Cruz</surname><given-names>J.</given-names></name></person-group><article-title>Ubiquitin and ubiquitin-like proteins and domains in ribosome production and function: Chance or necessity?</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>4359</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22094359</pub-id><pub-id pub-id-type="pmid">33921964</pub-id><pub-id pub-id-type="pmcid">PMC8122580</pub-id></element-citation></ref><ref id="B142-ijms-27-00362"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stepanchick</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cavanaugh</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Rothblum</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Rothblum</surname><given-names>L.I.</given-names></name></person-group><article-title>DNA binding by the ribosomal DNA transcription factor rrn3 is essential for ribosomal DNA transcription</article-title><source>J. Biol. Chem.</source><year>2013</year><volume>288</volume><fpage>9135</fpage><lpage>9144</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.444265</pub-id><pub-id pub-id-type="pmid">23393135</pub-id><pub-id pub-id-type="pmcid">PMC3610986</pub-id></element-citation></ref><ref id="B143-ijms-27-00362"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lauria</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bernab&#242;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tebaldi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Groen</surname><given-names>E.J.N.</given-names></name><name name-style="western"><surname>Perenthaler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maniscalco</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Donzel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Clamer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marchioretto</surname><given-names>M.</given-names></name></person-group><article-title>SMN-primed ribosomes modulate the translation of transcripts related to spinal muscular atrophy</article-title><source>Nat. Cell Biol.</source><year>2020</year><volume>22</volume><fpage>1239</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1038/s41556-020-00577-7</pub-id><pub-id pub-id-type="pmid">32958857</pub-id><pub-id pub-id-type="pmcid">PMC7610479</pub-id></element-citation></ref><ref id="B144-ijms-27-00362"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaiswal</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lomelino</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>McKenna</surname><given-names>R.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>P.</given-names></name><name name-style="western"><surname>Narayan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hromas</surname><given-names>R.</given-names></name></person-group><article-title>The splicing component ISY1 regulates APE1 in base excision repair</article-title><source>DNA Repair</source><year>2020</year><volume>86</volume><fpage>102769</fpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2019.102769</pub-id><pub-id pub-id-type="pmid">31887540</pub-id><pub-id pub-id-type="pmcid">PMC7185567</pub-id></element-citation></ref><ref id="B145-ijms-27-00362"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name></person-group><article-title>DCAF13 inhibits the p53 signalling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2024</year><volume>43</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1186/s13046-023-02936-2</pub-id><pub-id pub-id-type="pmid">38163876</pub-id><pub-id pub-id-type="pmcid">PMC10759521</pub-id></element-citation></ref><ref id="B146-ijms-27-00362"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name></person-group><article-title>Doxorubicin promotes breast cancer cell migration and invasion via DCAF13</article-title><source>FEBS Open Bio</source><year>2022</year><volume>12</volume><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.13330</pub-id><pub-id pub-id-type="pmcid">PMC8727929</pub-id><pub-id pub-id-type="pmid">34775691</pub-id></element-citation></ref><ref id="B147-ijms-27-00362"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name></person-group><article-title>UBE2N promotes cell viability and glycolysis by promoting Axin1 ubiquitination in prostate cancer cells</article-title><source>Biol. Direct</source><year>2024</year><volume>19</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/s13062-024-00469-y</pub-id><pub-id pub-id-type="pmid">38715121</pub-id><pub-id pub-id-type="pmcid">PMC11075218</pub-id></element-citation></ref><ref id="B148-ijms-27-00362"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name></person-group><article-title>Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancer</article-title><source>Front. Oncol.</source><year>2023</year><volume>12</volume><elocation-id>1002186</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2022.1002186</pub-id><pub-id pub-id-type="pmid">36793346</pub-id><pub-id pub-id-type="pmcid">PMC9922894</pub-id></element-citation></ref><ref id="B149-ijms-27-00362"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>P.-F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.-F.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>C.-W.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Liou</surname><given-names>H.-H.</given-names></name><name name-style="western"><surname>Ger</surname><given-names>L.-P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.-L.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>B.-H.</given-names></name></person-group><article-title>UBE2C is a potential biomarker for tumorigenesis and prognosis in tongue squamous cell carcinoma</article-title><source>Diagnostics</source><year>2020</year><volume>10</volume><elocation-id>674</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics10090674</pub-id><pub-id pub-id-type="pmid">32899896</pub-id><pub-id pub-id-type="pmcid">PMC7555092</pub-id></element-citation></ref><ref id="B150-ijms-27-00362"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rouette</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trofimov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haberl</surname><given-names>D.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lavall&#233;e</surname><given-names>V.-P.</given-names></name><name name-style="western"><surname>D&#8217;Angelo</surname><given-names>G.</given-names></name><name name-style="western"><surname>H&#233;bert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sauvageau</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lemieux</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perreault</surname><given-names>C.</given-names></name></person-group><article-title>Expression of immunoproteasome genes is regulated by cell-intrinsic and&#8211;extrinsic factors in human cancers</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>34019</fpage><pub-id pub-id-type="doi">10.1038/srep34019</pub-id><pub-id pub-id-type="pmid">27659694</pub-id><pub-id pub-id-type="pmcid">PMC5034284</pub-id></element-citation></ref><ref id="B151-ijms-27-00362"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R.</given-names></name></person-group><article-title>High SGO2 expression predicts poor overall survival: A potential therapeutic target for hepatocellular carcinoma</article-title><source>Genes</source><year>2021</year><volume>12</volume><elocation-id>876</elocation-id><pub-id pub-id-type="doi">10.3390/genes12060876</pub-id><pub-id pub-id-type="pmid">34200261</pub-id><pub-id pub-id-type="pmcid">PMC8226836</pub-id></element-citation></ref><ref id="B152-ijms-27-00362"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maerki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Olma</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Staubli</surname><given-names>T.</given-names></name><name name-style="western"><surname>Steigemann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gerlich</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Quadroni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sumara</surname><given-names>I.</given-names></name><name name-style="western"><surname>Peter</surname><given-names>M.</given-names></name></person-group><article-title>The Cul3&#8211;KLHL21 E3 ubiquitin ligase targets Aurora B to midzone microtubules in anaphase and is required for cytokinesis</article-title><source>J. Cell Biol.</source><year>2009</year><volume>187</volume><fpage>791</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1083/jcb.200906117</pub-id><pub-id pub-id-type="pmid">19995937</pub-id><pub-id pub-id-type="pmcid">PMC2806313</pub-id></element-citation></ref><ref id="B153-ijms-27-00362"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.-B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.-L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.-B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.-N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.-G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.-Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.-F.</given-names></name></person-group><article-title>KLHL21 suppresses gastric tumourigenesis via maintaining STAT3 signalling equilibrium in stomach homoeostasis</article-title><source>Gut</source><year>2024</year><volume>73</volume><fpage>1785</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2023-331111</pub-id><pub-id pub-id-type="pmid">38969490</pub-id></element-citation></ref><ref id="B154-ijms-27-00362"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golebiowski</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kasprzak</surname><given-names>K.S.</given-names></name></person-group><article-title>Inhibition of core histones acetylation by carcinogenic nickel (II)</article-title><source>Mol. Cell. Biochem.</source><year>2005</year><volume>279</volume><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1007/s11010-005-8285-1</pub-id><pub-id pub-id-type="pmid">16283522</pub-id></element-citation></ref><ref id="B155-ijms-27-00362"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loscalzo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Handy</surname><given-names>D.E.</given-names></name></person-group><article-title>Epigenetic modifications: Basic mechanisms and role in cardiovascular disease (2013 Grover Conference series)</article-title><source>Pulm. Circ.</source><year>2014</year><volume>4</volume><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1086/675979</pub-id><pub-id pub-id-type="pmid">25006435</pub-id><pub-id pub-id-type="pmcid">PMC4070783</pub-id></element-citation></ref><ref id="B156-ijms-27-00362"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaillou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>J.J.</given-names></name></person-group><article-title>Ribosome biogenesis: Emerging evidence for a central role in the regulation of skeletal muscle mass</article-title><source>J. Cell. Physiol.</source><year>2014</year><volume>229</volume><fpage>1584</fpage><lpage>1594</lpage><pub-id pub-id-type="doi">10.1002/jcp.24604</pub-id><pub-id pub-id-type="pmid">24604615</pub-id><pub-id pub-id-type="pmcid">PMC4868551</pub-id></element-citation></ref><ref id="B157-ijms-27-00362"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>S.-P.</given-names></name><name name-style="western"><surname>Denicourt</surname><given-names>C.</given-names></name></person-group><article-title>The impact of ribosome biogenesis in cancer: From proliferation to metastasis</article-title><source>NAR Cancer</source><year>2024</year><volume>6</volume><fpage>zcae017</fpage><pub-id pub-id-type="doi">10.1093/narcan/zcae017</pub-id><pub-id pub-id-type="pmid">38633862</pub-id><pub-id pub-id-type="pmcid">PMC11023387</pub-id></element-citation></ref><ref id="B158-ijms-27-00362"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>M.</given-names></name></person-group><article-title>XRCC 3 is a promising target to improve the radiotherapy effect of esophageal squamous cell carcinoma</article-title><source>Cancer Sci.</source><year>2015</year><volume>106</volume><fpage>1678</fpage><lpage>1686</lpage><pub-id pub-id-type="doi">10.1111/cas.12820</pub-id><pub-id pub-id-type="pmid">26383967</pub-id><pub-id pub-id-type="pmcid">PMC4714664</pub-id></element-citation></ref><ref id="B159-ijms-27-00362"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>L.</given-names></name><name name-style="western"><surname>Davalos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schiestl</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Campisi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oshima</surname><given-names>J.</given-names></name></person-group><article-title>WRN, the protein deficient in Werner syndrome, plays a critical structural role in optimizing DNA repair</article-title><source>Aging Cell</source><year>2003</year><volume>2</volume><fpage>191</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1046/j.1474-9728.2003.00052.x</pub-id><pub-id pub-id-type="pmid">12934712</pub-id></element-citation></ref><ref id="B160-ijms-27-00362"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer</article-title><source>Genes Dis.</source><year>2024</year><volume>11</volume><fpage>218</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.gendis.2022.11.022</pub-id><pub-id pub-id-type="pmid">37588202</pub-id><pub-id pub-id-type="pmcid">PMC10425756</pub-id></element-citation></ref><ref id="B161-ijms-27-00362"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hayes</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Dinkova-Kostova</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Tew</surname><given-names>K.D.</given-names></name></person-group><article-title>Oxidative stress in cancer</article-title><source>Cancer Cell</source><year>2020</year><volume>38</volume><fpage>167</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.06.001</pub-id><pub-id pub-id-type="pmid">32649885</pub-id><pub-id pub-id-type="pmcid">PMC7439808</pub-id></element-citation></ref><ref id="B162-ijms-27-00362"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmed</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Gogal</surname><given-names>R.M.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Walsh</surname><given-names>J.E.</given-names></name></person-group><article-title>A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: An alternative to [3H] thymidine incorporation assay</article-title><source>J. Immunol. Methods</source><year>1994</year><volume>170</volume><fpage>211</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(94)90396-4</pub-id><pub-id pub-id-type="pmid">8157999</pub-id></element-citation></ref><ref id="B163-ijms-27-00362"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsherbiny</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bhuyan</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Low</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.G.</given-names></name></person-group><article-title>Synergistic interactions of cannabidiol with chemotherapeutic drugs in mcf7 cells: Mode of interaction and proteomics analysis of mechanisms</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>10103</elocation-id><pub-id pub-id-type="doi">10.3390/ijms221810103</pub-id><pub-id pub-id-type="pmid">34576262</pub-id><pub-id pub-id-type="pmcid">PMC8469885</pub-id></element-citation></ref><ref id="B164-ijms-27-00362"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dissanayake</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Alsherbiny</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Bhuyan</surname><given-names>D.J.</given-names></name></person-group><article-title>Antiproliferative effects of Australian native plums against the MCF7 breast adenocarcinoma cells and UPLC-qTOF-IM-MS-driven identification of key metabolites</article-title><source>Food Biosci.</source><year>2023</year><volume>54</volume><fpage>102864</fpage><pub-id pub-id-type="doi">10.1016/j.fbio.2023.102864</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-27-00362-f001" orientation="portrait"><label>Figure 1</label><caption><p>CI values of different inhibitory concentrations of APB+Dox on AGS gastric cancer cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-27-00362-g001.jpg"/></fig><fig position="float" id="ijms-27-00362-f002" orientation="portrait"><label>Figure 2</label><caption><p>Pathway enrichment analysis using differentially expressed proteins in Dox-treated AGS cells compared to control cells. (<bold>A</bold>) Volcano plot showing significantly regulated proteins (absolute log2FC &#8805; 0.58 and Q &#8804; 0.05). (<bold>B</bold>) Graphical summary of top predictions in ingenuity pathway analysis (IPA) interpret report as derived from IPA core analysis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-27-00362-g002.jpg"/></fig><fig position="float" id="ijms-27-00362-f003" orientation="portrait"><label>Figure 3</label><caption><p>A schematic representation of the major pathway of rRNA processing in the nucleolus and cytosol. Proteins indicated in red were significantly upregulated, while proteins indicated in blue were downregulated in Dox-treated AGS cells compared to control untreated cells. The figure was generated by Qiagen Ingenuity Pathway Analysis (IPA).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-27-00362-g003.jpg"/></fig><fig position="float" id="ijms-27-00362-f004" orientation="portrait"><label>Figure 4</label><caption><p>Pathway enrichment analysis using differentially expressed proteins in APB+Dox-treated AGS cells compared to APB and Dox (Q &#8804; 0.05). (<bold>A</bold>) Volcano plot showing significantly regulated proteins (absolute log2FC &#8805; 0.58 and Q &#8804; 0.05). (<bold>B</bold>) Graphical summary of top predictions in an IPA Interpret report presented in the form of a simple network.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-27-00362-g004.jpg"/></fig><fig position="float" id="ijms-27-00362-f005" orientation="portrait"><label>Figure 5</label><caption><p>Network analysis of differentially expressed proteins involved in tumour progression following APB+Dox treatment in AGS cells compared to monotreatments APB and Dox.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-27-00362-g005.jpg"/></fig><fig position="float" id="ijms-27-00362-f006" orientation="portrait"><label>Figure 6</label><caption><p>Flow cytometric assessment of the apoptotic profiles of the AGS gastric cancer cells after 24 h of treatment. (<bold>A</bold>) The live, early apoptotic, late apoptotic, and necrotic cell percentages after 24 h treatment with APB (3000 &#181;g/mL), Dox (0.54 &#181;g/mL), APB+Dox (3000.27 &#181;g/mL), and control (n = 4). ** Indicates 0.01 &lt; <italic toggle="yes">p</italic>-value &lt; 0.05; *** indicates <italic toggle="yes">p</italic> &lt; 0.001; **** indicates <italic toggle="yes">p</italic> &lt; 0.0001 compared to the negative control. (<bold>B</bold>) Represented are the density plots of each drug treatment that is most representative of the average data from the flow cytometric analyses, with Q3-1 = necrotic cells, Q3-2 = late-stage apoptotic cells, Q3-3 = live cells, and Q3-4 = early-stage apoptotic cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-27-00362-g006.jpg"/></fig><fig position="float" id="ijms-27-00362-f007" orientation="portrait"><label>Figure 7</label><caption><p>Fold change in ROS generation following treatment with various concentrations: 3000:0.27 &#956;g/mL, 1500:0.14 &#956;g/mL, and 750:0.07 &#956;g/mL of APB+Dox. Additionally, Doxorubicin (0.54, 0.27, 0.14 &#956;g/mL) and tert-Butyl hydroperoxide (TBHP) (22.5 &#956;g/mL or 250 &#956;M) are included for comparative purposes. The values are expressed as mean &#177; SD. **** indicates <italic toggle="yes">p</italic> &lt; 0.0001 compared to untreated control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-27-00362-g007.jpg"/></fig><table-wrap position="float" id="ijms-27-00362-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-27-00362-t001_Table 1</object-id><label>Table 1</label><caption><p>Cell growth inhibition (%) against the AGS gastric adenocarcinoma and cell viability (%) of the Hs 738.St/Int normal intestine cell lines at different concentrations of APB combination, doxorubicin (Dox), combination APB+Dox, and combination for 72 h using the Alamar Blue assay (n = 3).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Conc.<break/>&#956;g/mL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell viability (%)<break/>HS738.St/Int</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Conc.<break/>&#956;g/mL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Growth Inhibition (%) of AGS Cels</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Viability (%)<break/>HS738.St/Int</th><th align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Conc.<break/>&#956;g/mL</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Growth Inhibition (%) of AGS Cels</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Viability (%)<break/>HS738.St/Int</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APB</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Dox</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">APB+Dox</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">3000</td><td align="center" valign="middle" rowspan="1" colspan="1">76.59 &#177; 8.56 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.54</td><td align="center" valign="middle" rowspan="1" colspan="1">73.51 &#177; 5.16 <sup>a</sup>
</td><td align="center" valign="middle" rowspan="1" colspan="1">38.37 &#177; 7.01 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">3000 + 0.27</td><td align="center" valign="middle" rowspan="1" colspan="1">103.46 &#177; 2.24 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">64.12 &#177; 8.76 <sup>a</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1500</td><td align="center" valign="middle" rowspan="1" colspan="1">79.67 &#177; 8.16 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" rowspan="1" colspan="1">34.69 &#177; 2.96 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">62.84 &#177; 11.53 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">1500 +0.136</td><td align="center" valign="middle" rowspan="1" colspan="1">102.51 &#177; 9.05 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">92.42 &#177; 10.66 <sup>b</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">750</td><td align="center" valign="middle" rowspan="1" colspan="1">80.98 &#177; 9.19 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.136</td><td align="center" valign="middle" rowspan="1" colspan="1">20.77 &#177; 7.29 <sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">68.52 &#177; 7.51 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">750 + 0.068</td><td align="center" valign="middle" rowspan="1" colspan="1">85.89 &#177; 8.58 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">100.54 &#177; 8.51 <sup>b</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">375</td><td align="center" valign="middle" rowspan="1" colspan="1">85.80 &#177; 13.04 <sup>a</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.068</td><td align="center" valign="middle" rowspan="1" colspan="1">17.29 &#177; 7.96 <sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">71.51 &#177; 7.81 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">375 + 0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">50.34 &#177; 8.49 <sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">105.92 &#177; 11.80 <sup>b</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">187.5</td><td align="center" valign="middle" rowspan="1" colspan="1">103.99 &#177; 10.54 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.034</td><td align="center" valign="middle" rowspan="1" colspan="1">9.77 &#177; 6.90 <sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">87.28 &#177; 9.25 <sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">187.5 + 0.017</td><td align="center" valign="middle" rowspan="1" colspan="1">28.04 &#177; 7.40 <sup>d</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">112.90 &#177; 11.32 <sup>b</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">93.75</td><td align="center" valign="middle" rowspan="1" colspan="1">117.67 &#177; 13.09 <sup>b</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 &#177; 3.84 <sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">89.33 &#177; 11.72 <sup>c</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">93.75 + 0.0085</td><td align="center" valign="middle" rowspan="1" colspan="1">27.29 &#177; 11.68 <sup>d</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">114.72 &#177; 11.16 <sup>b</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>IC<sub>50</sub></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>&gt;3000</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>IC<sub>50</sub></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>0.22 &#177; 0.04</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>&gt;0.27</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>IC<sub>50</sub></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>512.80 &#177; 18.37</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>&gt;3000.27</bold>
</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a,b,c,d</sup> The different superscript values in the same column for each cell line indicate statistically significant difference (<italic toggle="yes">p</italic> &lt; 0.05) compared to the highest concentration (3000 &#956;g/mL).</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>